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1. INTRODUCTION
1.1 Acute retinal necrosis (ARN) 
ARN  syndrome  is  a  well-known  clinical  entity  that  was  first  described  in  1971 
(Urayama  et  al.,  1971).  ARN is  a  type  of  retinitis  that  affects  both  healthy  and 
immunocompromised  patients  (Silverstein  et  al.,  1997;  Batisse  et  al.,  1996; 
Nussenblatt et al., 1989). Patients typically experience blurred vision, eye pain, and 
light sensitivity, in one or sometimes both eyes. Several members of the herpes virus 
family including herpes simplex virus (HSV)-1, HSV-2, varicella zoster virus (VZV) 
and, rarely, cytomegalovirus (CMV) are the main causing viruses (Silverstein et al., 
1997; Atherton et al., 2001;  Lewis et al., 1989; Thompson et al., 1994; Hellinger et 
al., 1993; Ganatra et al., 2000).
1.1.1 Virology of herpes viruses
They all have a large number of enzymes available that are involved in nucleic acid 
metabolism, DNA synthesis, and possibly the procession of proteins. The synthesis of 
DNA and the assembly of the capsid take place in the nucleus. The production of 
infectious virus particles may lead to the destruction of the infected cell. Furthermore, 
the herpes  viruses establish latent  infection in  their  natural  hosts  (Roizman et  al., 
1996). During latency, the herpes virus genomes form closed circular molecules, and 
only a small number of viral proteins are expressed. There is evidence that selected 
regulatory genes are active and may maintain latency, but neither the mechanisms to 
keep the status of latency nor the factors that cause reactivation of viral replication are 
yet  completely  known.  After  reactivation,  infectious  viruses  are  transported  to 
peripheral tissues, e.g., by axonal transport in HSV infection (or retrograde transport 
back  to  the  locus  of  primary  infection).  The  immune  response  of  the  host  may 
determine whether reactivation may result in a symptomatic or asymptomatic course 
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of herpetic disease (Roizman et al., 1996; Roizman & Sears , 1996)
1.1.2 Pathogenesis of HSV-1 induced experimental acute retinal necrosis
The acute stage of ARN is characterized by necrotizing retinitis of all retinal layers. 
The retinal vessels in the diseased area show fibrinoid necrosis of the vessel wall and 
vascular occlusion. The retinal pigment epithelium (RPE) shows focal necrosis and is 
occasionally  separated  from Bruch’s  membrane.  The necrotizing  retinal  cells  may 
reach the overlying vitreous body, where inflammatory cells  group around it.  The 
necrotizing retina is mostly sharply demarcated adjacent to the intact retina. In the 
marginal areas, intranuclear inclusions can be noted histologically, and by electron 
microscopy, virus particles can be detected in the retinal cells (Minckler et al., 1976; 
Cibis et al.,1978; Johnson et al.,1977). The adjacent choroid shows severe choroiditis 
with vascular occlusions. At the same time, optic nerve neuritis and papillitis arises. 
Inflammatory cells are infiltrating the aqueous humor and the anterior chamber angle. 
The iris and ciliary body show non-granulomatous and granulomatous cell infiltration 
and perivasculitis (Culbertson et al., 1982; Naumann et al., 1968; Culbertson et al., 
1986). In the healing phase, the process leads to complete disintegration of the retina 
and the optic nerve, with reactive metaplasia of the retinal pigment epithelium (Cogan 
et al., 1964; Rummelt et al., 1992).
Herpes viruses were demonstrated in the retinal lesions and vitreous body in ARN 
patients by culture methods, histology, electron microscopy, immunohistochemistry, 
and by  polymerase  chain-reaction  methods (Lewis  et  al.,  1989;  Culbertson  et  al., 
1982; Pavan-Langston & Dunkel, 1989; Forster et al., 1990; Culbertson et al., 1986; 
Pepose  &  Whittum-Hudson,  1987).  After  primary  infection  or  reactivation  from 
latency,  herpes  virus  replication follows.  From animal  experiments  (Forster  et  al., 
1990) it is known that viruses migrate through the ipsilateral parasympathetic fibers of 
the oculomotor  nerve  that  serve  the iris  and ciliary bodies  in  the central  nervous 
system. The viral replication within the CNS is fairly well limited to the nucleus of 
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the visual system and to the suprachiasmatic area of the hypothalamus. Viruses than 
migrate from the brain to the retina via retrograde axonal transport through the optic 
nerve,  along  the  endocrine-optic  path  between  the  retina  and  the  suprachiasmatic 
nucleus of the hypothalamus.
At this site, the viral invasion can spread out to the contralateral regions, which may 
explain  the  involvement  of  the  fellow eye  in  patients  with  bilateral  acute  retinal 
necrosis (BARN). Along the optic nerve, the viruses may also reach the ganglionic 
cells of the contralateral retina (Pettit et al., 1965). 
The retinal pathology represents a viral-induced cytopathology (Holland et al., 1987; 
Whittum-Hudson & Pepose, 1987). However, the accompanying immune reactions 
are  decisive  for  the  further  inflammatory  process  that  finally  results  in  the 
development of retinal necrosis (Holland et al., 1987.; Whittum et al., 1984). Local as 
well as systemic factors come into effect here (Whittum et al.,  1984). It  has been 
shown  that  the  retinal  HSV infection  is  under  the  control  of  T  lymphocytes  in 
experimental  herpetic retinitis  (Whittum-Hudson et  al.,  1985).  A contribution of T 
lymphocytes in the pathogenesis of human ARN has been suggested (Verjans et al., 
1998).
The severe vascular occlusions lead to ischemia of the retina and choroid and further 
promote the development  of necrosis.  The massive breakdown of the blood-retina 
barrier with the resulting increase of the protein content in the vitreous is associated 
with a proliferative effect on the pigment epithelium and the fibroblasts.  This may 
further  support  the  development  of  proliferative  vitreoretinopathy  (PVR).  The 
necrotic-related retinal tears and the developing traction from the vitreous space then 
finally result in the emergence of retinal detachment.
1.2 von Szily model
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von Szily was the first scientist who reported about acute retinal necrosis syndrome in 
rabbits in 1924 (Von Szily, 1924). After injecting replication herpes simplex virus into 
the right anterior chamber of a rabbit, a rapidly destructive retinitis of the opposite 
(left)  eye developed. The histopathologic  analysis  of the inoculated eye,  however, 
disclosed that the retina of the injected (right) eye was more or less completely spared 
of this destructive phenomenon.  
It  has  been  shown that  inoculation  of  the  KOS strain  of  HSV-1 into  the  anterior 
chamber of one eye of BALB/c mice induced characteristic retinal changes, including 
a devastating inflammatory reaction within the posterior segment of the uninoculated 
eye,  resulting  in  pan-necrosis  of  the  retina  10  to  14  days  post  inoculation  (PI) 
(Whittum et al., 1984).
Diverse  inbred  strains  of  mice  have  been  shown  to  vary  considerably  in  their 
resistance  and  susceptibility  to  that  HSV induced  retinal  necrosis  syndrome.  The 
different strains of BALB/c, C57BL/6 and F1 hybrid had been studied to define the 
resistance and susceptibility to HSV retinitis. Injected eyes of BALB/c mice showed 
an anterior uveitis with HSV-1 antigens in the anterior segment and an intact retina 
that  was  free  of  HSV antigens.  The  retina  of  the  contralateral  uninjected  eye,  in 
contrast, was necrotic and contained HSV-1 antigens. In both, C57BL/6 and F1 mice, 
HSV antigens were limited to the structures of the anterior segment in the injected 
eye,  whereas,  in  contrast  to  BALB/c  mice,  the  contralateral  retina  appeared 
histologically normal and contained no viral antigens. Furthermore, these strains also 
remained relatively resistant to retinal infection despite being immunosuppressed by 
radiation (Pepose et al., 1987; Whittum & Pepose, 1988). Another study showed that 
DBA/2 mice were mildly resistant to HSV-1 retinitis in the uninoculated eye (Kielty 
et al., 1987).
Although HSV inoculated into anterior chamber of mouse in general induced retinitis, 
the different strains of HSV induced different courses of that disease. Whereas HSV-1 
produces  a  rapid,  explosive  retinitis  that  led  to  destruction  of  all  cell  layers  of 
contralateral  retina,  HSV-2 induced a retinitis  in the ipsilateral  eye that was more 
4
gradual in onset (Dix et al., 1987).
Inoculation  of  HSV-1  (KOS)  into  the  anterior  chamber  of  BALB/c  mouse  eyes 
produces an intense inflammatory reaction at the inoculation site. Intensity and speed 
of the inflammatory reaction are dose-dependent over a wide range: 2×102 to 2×105 
plaque  forming  units  (PFU)  HSV-1.  The  dose  of  2×104 PFU was  chosen  by  the 
researchers for the following reasons: (1) this particular dose of virus induced anterior 
chamber-associated immune deviation (ACAID), i.e., recipient mice produced high 
titers of circulating anti-HSV-1 antibody, but failed to develop T-cell immunity as 
measured by the capacity to express HSV-1 specific delayed type hypersensitivity 
(DTH);  (2)  when  inoculated  subcutaneously,  this  dose  of  virus  regularly  induced 
vigorous  DTH  to  HSV-1  as  well  as  humoral  anti-HSV-1  responses;  and  (3)  lid 
vesicles were observed uncommonly after AC inoculation of 2×104PFU HSV, whereas 
at  higher  doses  lid  lesions  regularly  occurred,  raising  the  possibility  that  auto-
inoculation of virus by infected mice would unduly confound the analysis. Within this 
dose range, the only visible manifestation of disease in AC-inoculated mice was in the 
injected  eye.  None  of  the  mice  died  or  developed signs  of  disease  at  other  sites 
(Whittum et al., 1983; Whittum et al.,1984).
In  the  HSV-1  inoculated  eyes,  the  inflammatory  reaction  commonly  involves  the 
entire anterior segment. The cornea rapidly becomes edematous, and an inflammatory 
cell infiltration and neovascularization occurs. The central stromal infiltrate peaks by 
day 7 and resolved completely by day 21. The extensive neovascularization reaches 
its maximum intensity by day 14. The extensive loss of corneal clarity observed by 
slit lamp corresponds with the edema and disruption of the stromal architecture. By 
day 5, the corneal endothelium is destroyed. The anterior chamber of injected eyes 
contains an increasingly severe cell and flare reaction that is already visible by 1 day 
after  virus inoculation. Over 21 days, the anterior chamber becomes progressively 
more shallow (loss of form or depth), and it  is occupied by a fibrovascular tissue 
development between day 14 and 21 PI. Iris infiltration and loss of iris integrity are 
both evident at day 1. Iris atrophy (loss of iris stroma and vessels) occurs by day 3 
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(Whittum et al., 1984).
In contralateral eye, the inflammatory reaction involves mainly the posterior segment. 
The infectious process in the retina of the uninoculated eye has been divided in three 
phases: acute retinitis, retinal necrosis, and resolution (Cousins et al., 1989). Acute 
retinitis is observed between days 7 and 9 PI. The retina remains normal until day 7 
PI. At this time, small foci of inflammatory cells appear around one or two small 
vessels  in  the  ganglion cell  layer  (GCL).  These  foci  are  limited  generally  to  one 
lateral aspect of the GCL per eye, midway between the optic nerve and the anterior 
edge of the retina (ora serrata). The remainder of the GCL appears normal at this time, 
as do the outer layers of the retina and underlying choroid.
The retinal necrosis begins on day 10 PI. By day 10, a large necrotic area containing a 
mixed  inflammatory  infiltrate  extends  posteriorly  through  the  entire  retina.  The 
choroid  underlying  the  necrotic  area  also  is  infiltrated.  Inflammatory  cells  can 
occasionally be seen around the optic nerve at this time. By day 14 PI, the retina is 
completely  necrotic  with  inflammatory  cells,  debris  and  numerous  plasma  cells 
interspersed  throughout  the  disrupted  retinal  cells.  In  addition,  the  choroid  is 
infiltrated extensively.
The resolution phase usually begins on or about day 15 PI. The remnants of the retina 
are  organized  into  a  fibrocellular  scar,  and  the  ocular  inflammation  is  gradually 
resolved (Azumi et al., 1994; Zaltas et al., 1992; Azumi & Atherton, 1998; Cousins et 
al., 1989). 
Following anterior chamber inoculation of HSV-1 into one eye of BALB/c mice, a 
certain pattern of ocular pathology as well as systemic immune response emerges. It is 
a  suppression  of  DTH  responses  to  the  injected  HSV  with  an  intact  HSV-1 
neutralizing  antibody  response.  This  phenomenon  is  termed  anterior  chamber 
associated immune deviation (Whittum et al.,  1983). However, compared with the 
BALB/c strain, the AC infection in C57BL/6 mice was not followed by a contralateral 
retinitis, while the mice showed a vigorous HSV-1 specific DTH response. Therefore, 
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is has been suggested that the absence of contralateral retinitis might be linked to the 
induction of virus-specific DTH response. It has been speculated that DTH inducing 
T-effector cells or other mechanisms might limit the amount of virus that reaches the 
CNS, which in turn affects the amount of second wave of virus which reaches to 
uninoculated contralateral eye (Kielty et al., 1987)
The virus culture studies have revealed that virus reaches the uninoculated eye in two 
temporally  separate  waves  after  uniocular  anterior  chamber  inoculation.  The  first 
wave of virus is detected in the uninoculated eye as early as one day PI, long before 
virus is found in either of the optic nerves or the brain. The second wave of virus 
arrives  in  the  uninoculated eye between 7 and 10 days  PI  (Atherton & Streilein, 
1987).
Kahn  (1993)  investigated  the  effect  of  light  onto  von  Szily  model.  His  findings 
suggested that virus does not reach the contralateral retina in dark-reared mice. He 
found a decrease in neuronal firing and retrograde axoplasmic flow during darkness 
(Kahn et al., 1993). Colchicine is known for its axonal-transport-blocking capabilities. 
It  was  used  to  examine  whether  virus  is  transported  via  the  optic  nerve  to  the 
uninoculated  eye  after  anterior  chamber  inoculation  of  HSV-1.  The  results 
demonstrated that blocking the optic nerve with colchicine prevented the entry of only 
the  second-wave  of  virus,  while  the  first-wave  of  virus  was  not  affected.  This 
observation  supported  the  hypothesis  that  the  second-wave  of  virus  reaches  the 
contralateral eye from the central nervous system via the optic nerve (Bosem et al., 
1990).
The route of second wave of virus spread was also studied by Vann and Atherton 
(Vann & Atherton, 1991) in BALB/c mice. The data showed that virus spreads from 
the injected eye to the central nervous system (CNS) through parasympathetic fibers 
of the oculomotor nerve that supply the iris and ciliary body. The virus spread in the 
CNS is limited primarily to the nuclei of the visual system and the suprachiasmatic 
area of the hypothalamus. Subsequently, the virus is transmitted from the CNS to the 
retina of the contralateral eye by retrograde axonal transport through the optic nerve 
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along the endocrine-optic pathway between the retina and the suprachiasmatic nucleus 
(SCN) of the hypothalamus (Fig 1).
1.3 Participation of the immune response to the injected virus
Researchers have concluded that immune response participates in the course of the 
HSV-1-induced contralateral retinitis (Atherton et al., 1989; Whittum-Hudson et al., 
1985). Using flow cytometry and immunohistochemistry, Azumi (Azumi & Atherton, 
1998) documented that T cell play a role in the disease. At day 9 PI (acute retinitis), T 
cells were observed in the uvea but not in the retina of contralateral eye. The CD4+ 
and CD8+ T cells were found in the sensory retina coincident with the onset of retinal 
necrosis (day 11 PI), and CD4+ and CD8+ T cells were then detected in the remnants 
of the retina until day 63 PI. The maximum number of infiltrating cell, both of the 
CD4+ and CD8+ subgroups were observed at day 21 PI. 
Another investigation by the same group of researchers suggested that the CD4+ T cell 
subset contributes to the destruction of the retina,  and may accelerate the cellular 
infiltration and inflammation-induced retinal destruction at day 14 (retinal necrosis 
phase). At least 2 weeks before inoculation of virus, T-cell-depleted BALB/c mice 
were  injected  intravenously  with  anti-CD4  monoclonal  antibody.  Indeed,  the 
treatment with an anti-CD4 monoclonal antibody in the von Szily model modified the 
virus recovery from the posterior segment of the contralateral eye significantly. By 
day 14 PI, significantly higher titers of virus were recovered from the mice that were 
depleted of CD4+ cells. In conclusion, the CD4+ T cells are involved in virus clearance 
from contralateral eye (Azumi et al., 1994).
The Mac-1 positive cells (macrophages, natural-killer cells, and polymorphonuclear 
neutrophils) appear in contralateral ciliary body between day 8 and 10 PI. On day 10, 
a  large  number  of  Mac-1 positive cells  infiltrate  the  retina,  and mainly  the  inner 
retinal layers. Simultaneously, Mac-1 positive cells also infiltrated the choroid. The 
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finding of a predominance of Mac-1 cells in the contralateral retina of susceptible 
BALB/c  mice  on  day  10  led  the  researchers  to  speculate  that  the  cells  might  be 
important mediators of necrotizing in contralateral retinal necrosis phase (Zaltas et al., 
1992). The DNA microarray results showed that macrophage-related genes were up-
regulated in the contralateral eye at day 9 PI. Additional immunohistochemical studies 
also showed the presence of F4/80-positive cells in the retina (Zheng et al., 2003). In 
further experiments, an anti-CD11b mAB was injected intravitreally before the first 
wave of inflammatory cells arrived to the eye. This resulted in a profound suppression 
of retinal necrosis with significant decrease in both the incidence and the severity of 
the  retinitis,  even  though  herpes  simplex  viral  particles  could  be  detected  in  the 
chorioretinal layers of unaffected eyes by indirect immunofluorescence. In agreement 
with these data, a suppression of retinal necrosis was also noted when macrophages 
were depleted from mice by the treatment with Cl2MDP-liposomes. The timing of the 
anti-CD11b mAb injection appeared to be critical for the inhibition of contralateral 
retinitis. Suppression of retinal necrosis was effective only when the antibody was 
administered  before  the  onset  of  clinical  signs.  Once  the  initial  clinical  signs  of 
contralateral retinitis were observed, anti-CD11b mAb did not alter the course of the 
disease (Berra et al.,1994). These findings suggested that macrophages are important 
participants in the effector phase of the inflammatory immune response in HSV-1 
induced contralateral retinitis. Macrophages probably play a multifunctional role in 
the pathogenesis of the disease by direct cytotoxic action and indirectly by releasing 
chemotactic  and  immunoregulatory  cytokines  that  finally  contribute  to  retinal 
destruction.  Other  possibilities  are  that  they are  acting as  antigen presenting cells 
(APC) to increase T-cell function (accessory function of macrophages). They can also 
provide costimulatory signals to increase effector T-cell function by B7.1/B7.2.
Beside  the  inflammatory  cells,  various  cytokines  and  chemokines  are  actively 
involved in the course of HSV-1 retinitis. DNA microarray was used to analyze the 
expression  patterns  of  genes  in  the  uninoculated  eye  following uniocular  anterior 
chamber inoculation of HSV-1. The most abundant cytokines and chemokines in the 
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contralateral  eyes  of  mice  with  HSV-1  retinitis  were  the  IFN-family  and  their 
receptors, the interleukins IL-1, IL-6, and IL-4 and their receptors, and macrophage 
inflammatory protein (MIP-1 and MIP-2) and their receptors. Since these cytokine 
and cytokine-receptor genes were up-regulated in the uninoculated eye at the peak of 
acute retinal infection, these results suggested that they are likely to be the modulators 
most  closely  related  to  ARN  (Zheng  et  al.,  2003).  From  RT-PCRs  assay,  the 
transcriptions  of  some cytokines  were  investigated.  IFN-g-mRNA was  moderately 
elevated on day 6 PI, increased slightly between days 6 and 8 PI, and then increased 
slightly again between day 8 and 11 PI. On day 6 and 8 PI, the level of mRNA for IL-
4 was only slightly above that observed in the uninjected eyes of the mock-infected 
mice. Between day 8 and 11 PI, the amount of IL-4 mRNA increased approximately 
three fold. IFN-γ+ and IL-4+ cells were observed throughout the retina. Most of CD4+, 
Gr-1+, CD19+ and F4/80+ cells expressed IFN-γ and IL-4 (Zheng et al., 2005).
1.4 Tumor necrosis factor-alpha
The proinflammatory cytokine tumor necrosis factor alpha (TNF-α) originally was 
identified as a serum factor causing hemorrhagic necrosis of tumors and inducing 
cachexia. TNF-α is now known to possess many cell-activating and pro-inflammatory 
activities. TNF-α is produced by many cell types, among them are macrophages, T 
cells,  and  natural  killer  cells.  The  pro-inflammatory  effects  include  induction  of 
expression or up-regulation of major histocompatibility complex molecules (Sartani et 
al.,  1996;  Fong  & Lowry,  1990;  Fleisher  et  al.,  1990).  TNF-α  exerts  its  actions 
through two distinct receptors: TNF RI (P55) and TNF RII (P75). The TNF-induced 
cytotoxicity  has been attributed in  the past  to the p55 receptor,  and TNF-induced 
proliferation to the p75 receptor.  However, it has been shown, that p75 can greatly 
enhance p55-induced cell death (Koizumi et al., 2003; Bigda et al., 1994; Tartaglia et 
al., 1991 ). 
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The TNF/TNF-R family plays a key role in the activation, differentiation and effector 
responses of T-cells. Subsequent analysis of TNF-R expression revealed that antigen 
activation was required for the up-regulation of p75 and to a lesser extent p55 TNF-R 
and the acquisition of TNF responsiveness by different T-cell subsets in vitro, but 
more importantly at sites of inflammation (Ware et al.,  1991; Brennan et al.,1992; 
Cope et al.,1995). Both in vitro and in vivo co-stimulatory effects may arise through 
different mechanisms, including activation and differentiation of antigen-presenting 
cells, such as dendritic cells, as well as antigen-presenting function (Sallusto et al., 
1995).  The  treatment  with  rabbit  anti-TNF-α  serum  in  experimental  autoimmune 
uveoretinitis  (EAU) during the afferent stage significantly reduced the autoantigen 
specific lymphocyte proliferation and DTH (Sartani et  al.,  1996).  Greiner and co-
workers  investigated  15  patients  with  posterior  segment  intraocular  inflammation 
(PSII) refractory to conventional immunosuppressive therapy and who then received a 
single infusion of a recombinant protein generated by fusing the p55 TNF-α receptor 
with human IgG1. Interestingly, the authors found that the anti-TNF-α agent induced 
an  up-regulation  of  IL-10-expression  in  peripheral  blood  CD4+ T  cells  and  an 
alteration in the ratio of IL-10- and IFN-γ-producing CD4+  T cells (Greiner et al., 
2004).
Macrophages are versatile cells that are intimately involved in diverse aspects of the 
immune response and inflammation. The cytotoxic macrophages and production of 
nitric  oxide  (NO)  or  reactive  oxygen  species  (ROS)  might  cause  cell  membrane 
peroxidation and destruction.  Classic  macrophage activation after  stimulation with 
IFN-γ and TNF refers to the ability of a macrophage to express nitric oxide synthase 
(NOS2) and generate nitrite, peroxynitrites, and superoxides, which in turn induce 
lipid peroxidation of cell membranes and cell death (Robertson et al., 2002; Erwing et 
al.,  1998;  Li  & Verma,  2002;  van  Strijp  et  al.,  1991).  In  experimental  cutaneous 
leishmaniasis,  the  blockade  of  the  TNF  activity  resulted  in  a  reduced  NOS2 
expression  from draining  lymph  nodes  and  macrophages  (Engwerda  et  al.,  2002; 
Fonseca et al., 2003). With a treatment of mice with sTNFr-IgG in the EAU model, 
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infiltrating  macrophages  reduced  expression  nitrite  production  at  the  height  of 
disease,  and the  level  of  apoptosis  within the  retina  was reduced too  (Robertson, 
2003).
In  the  von  Szily  model,  TNF-α  mRNA and  protein  was  up-regulated  during  the 
evolution of ARN (from day 6 to 14 PI) in the contralateral eyes compared with levels 
in control subjects  (Zheng et  al.,  2005). The DNA microarray results showed that 
among the most up-regulated cytokines and chemokines in contralateral eye of mice 
with HSV-1 retinitis was the TNF family cytokines and their receptors (Zheng et al., 
2003).  The  immunohistochemical  stainings  revealed that  TNF-α was produced by 
infiltrating cells  such as CD4+,  Gr-1+,  CD19+,  and F/80+ cells.  Approximately one 
third of the RPE cells produced TNF-α at day 9 PI. In addition, a smaller number (4-
14%) of Müller cells also produced TNF-α at the same time (Zheng et al., 2005). 
Latently infected trigeminal ganglia (strain KOS) were excised and placed in vitro. 
TNF-α was added daily. The reactivation replication rate in the TNF-α treated group 
was  higher  than  the  control  group.  These  experiments  demonstrated  that  TNF-α 
enhanced the reactivation frequency and replication of  HSV (Walev et  al.,  1995). 
Also,  the  number  of  TNF-α  producing  cells  was  investigated  during  the  acute 
replication phase of HSV in trigeminal ganglia. The appearance of TNF-α producing 
cells  in the trigeminal ganglia was correlated to virulence and replication of HSV 
dependent on the time of appearance. The higher the virulence the earlier commenced 
replication and the more increased the number of TNF-α- producing cells (Walev et 
al., 1995).
In conclusion, it appears that TNF-α is an one of the most important pro-inflammatory 
cytokines in ARN (Oettinger & D’Szouza, 2003).
1.5 Antisense technologies
Scientists have been working on strategies to selectively turn off specific genes in 
diseased tissues for the past thirty years. The potential of oligodeoxynucleotides to act 
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as antisense agents that  inhibit  viral  replication in  cell  culture  was discovered by 
Zamecnik  and Stephenson in  1978 (Zamecnik  et  al.,  1978).  Since  then  antisense 
technology has been developed as a powerful tool for target validation and therapeutic 
purposes. Theoretically, antisense molecules could be used to cure any disease that is 
caused by the expression of a deleterious gene, such as viral infections, cancer growth 
and  inflammatory  diseases.  In  the  1980's,  oligodeoxynucleotides  with  unique 
chemistries were tested in experimental model systems both in vitro and in vivo with 
varying degrees of success. In the 1990's, ribozymes with both antisense and catalytic 
properties  were  successfully  introduced  to  the  field.  Ribozymes  were  shown  to 
selectively knock-down targeted genes in human tumors grown in mice, but delivery 
issues for these therapeutic anti-genes limited their clinical utility. Short interfering 
RNA (siRNA) is currently a growing sector of this anti-gene research field for target 
validation and therapeutic applications. 
Three types of anti-mRNA strategies are summarized in Fig 2. Most of conventional 
drugs  bind to  proteins  and  thereby modulate  their  function.  In  contrast,  antisense 
agents  act  at  the  mRNA level,  preventing  its  translation  into  protein.  Antisense 
oligonucleotides pair with their complementary mRNA, whereas ribozymes and DNA 
enzymes are catalytically active oligonucleotides that not only bind, but also cleave 
their target RNA. In recent years, the development of novel chemical modifications 
stabilized oligonucleotides. It enhanced the target affinity too. RNA interference is an 
efficient  method  for  suppressing  gene  expression  by  the  use  of  21-23-mer  small 
interfering RNA (siRNA) molecules (Elbashir et al., 2001).
Antisense molecules are commonly composed of single-stranded DNA, which they 
are termed antisense oligonucleotides (ASON). The ASON usually consist of 15-20 
nucleotides,  which  is  complementary  to  their  target  mRNA.  The  mechanisms  of 
action include blockage of translation and splicing. The RNA-DNA hybrid can also be 
recognized and cleaved by RNase H, yielding an additional mechanism of repression 
of gene expression. Alternatively, ASON that do not induce RNase H cleavage can be 
used to inhibit translation by blockade of the ribosome. When the ASON are targeted 
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to  the  5’-terminus,  binding  and  assembly  of  the  translation  machinery  can  be 
prevented  (Fig  3).  The  antisense-mediated  inhibition  of  gene  expression  raised 
considerable interest in the potential of antisense molecules not just as a molecular 
tool in biomedical research, but also as a novel class of therapeutic agent (Scanlon, 
2004).
One  of  the  major  challenges  for  antisense  approaches  is  the  stabilization  of 
oligonucleotides. If used in their unmodified form as phosphodiesters, they are rapidly 
degraded in biological fluids by nucleases. There are a vast number of chemically 
modified  nucleotides  that  have  been  used  previously  in  antisense  experiments.  In 
general, three types of modifications of ribonucleotides can be distinguished: analogs 
with unnatural bases, modified sugars or altered phosphate backbones. In the recent 
years, a variety of modified nucleotides have been developed to improve properties 
such  as  target  affinity,  nuclease  resistance  and  pharmacokinetics.  DNA and  RNA 
analogs with modified phosphate linkages or riboses, as well as nucleotides with a 
completely  different  chemical  moiety  substituting  the  furanose  ring  (Galderisi  & 
Cascino, 1999; Pierce et al., 2005; Da Ros et al., 2005).
An important hurdle that has to be overcome for successful antisense applications, is 
the cellular uptake of the molecules. In cultured cells, internalization of naked DNA is 
usually  inefficient,  due  to  the  fact  that  charged  oligonucleotides  have  to  cross  a 
hydrophobic cell membrane. A number of methods have, therefore, been developed 
for in vitro and in vivo delivery on oligonucleotides. By far the most commonly and 
successfully used delivery systems are liposomes and charged lipids, which can either 
encapsulate  nucleic  acids  within  their  aqueous  center,  or  form  lipid-nucleic  acid 
complexes as a result of opposing charges. These complexes are usually internalized 
by endocytosis (Kurreck, 2003).
It has been recently shown that TNF-α-ASON diminishes the release of TNF-α from 
cultured  draining  lymph  node  cells  or  splenocytes  (Wasmuth  et  al.,  2003). 
Furthermore, the corneal injection of TNF-α-ASON significantly improved the course 
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of herpetic stromal keratitis (HSK). TNF-α-ASON effectively suppressed the content 
of TNF-α in the HSV-1 infected corneas.
1.6 Aim of this study
In this study, mice were infected in the AC of the right eyes with HSV-1 (von Szily 
model), and the left eyes were treated subconjunctivally with ASON targeting TNF-α 
Experiments were performed to answer the following questions:
1. Is TNF-α-ASON taken up into the eyes when injected subconjunctivally? (in the 
injected eyes, in regional lymph nodes and spleen)
2. Is TNF-α-ASON treatment influencing the expression of TNF-α in vivo? (in the 
injected eyes)
3.  Is TNF-α-ASON able to modify the severity of contralateral retinitis? What is an 
appropriate treatment plan?
4. What is the effective way of modifying the course of contralateral retinitis by TNF-
α-ASON administration? (comparison of subconjunctival and intraocular injections)
5. Is TNF-α-ASON modifying the intraocular inflammatory cell infiltration?
6. Is TNF-α-ASON affecting the systemic immune response against HSV-1?
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2. MATERIALS AND METHODS
2.1 Reagents
[3H]Thymidine Amersham Bioscience, Buckinghamshire, 
UK
3-Amino-9-Ethylcarbazol Sigma-Aldrich Chemie GmbH, Germany
β-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Germany
Acetic acid Merck KGaA,, Germany
Acetone Merck KGaA,, Germany
Agarose Sigma-Aldrich Chemie GmbH, Germany
APES (3-aminopropyltriethoxysilane) Sigma-Aldrich Chemie GmbH, Germany
Aquatex Merck KgaA, Germany
Concanavalin (Con) A Sigma-Aldrich Chemie GmbH, Germany 
Crystal violet Merck KGaA, Germany
Ethanol Carl Roth GmbH, Germany
Eosin Sigma Diagnostics, USA
Eukitt Sigma-Aldrich Chemie GmbH, Germany
Fetal calf serum DAKO, A/S, Denmark
Formaldehyde sodium 37% Merck KGaA, Germany
Hematoxylin solution, Gill No.3 Sigma Diagnostics, USA
HEPES Roth, Karlsruhe, Germany
Hydrogen Peroxide PharMingen, Heidelberg, Germany
Ketamine hydrochloride CuraMED Pharma GmbH, Germany
Mepivacaine hydrochloride CuraMED Pharma GmbH, Germany
Natrium chlorid Merck KGaA, Germany
N,N-Dimethylformamid Sigma-Aldrich Chemie GmbH, Germany
Normal mouse serum DAKO, A/S, Denmark
PBS Gibco Brc, Germany
Paraformaldehyde Sigma-Aldrich Chemie GmbH, Germany
RPMI YIB CO, Germany
Scandicain 2% AstraZeneca GmbH, Germany
Sterile saline solution Bayer, Germany
Sodium acetate Sigma-Aldrich Chemie GmbH, Germany
Tetramethylbenzidine (TMB) PharMingen, Heidelberg, Germany
Tween-20 0.05% PharMingen, Heidelberg, Germany
Xylol Merck KGaA,, Germany
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2.2 Instruments
Frigocut cryostat Reichert-Jung 2800N, Germany
Flow cytometry FACScan  Flow  Analyser  (Becton 
Dickinson San Jose, CA)
Microscope Olympus BX40F4, Japan
Microtome Leica RM 2135, Germany
Fluorescence microscopy Olympus BX40F4, Japan
Microtiter Plate Reader MRX Dynatech  Laboratories,  Chantilly,  VA, 
USA
Scintillation Counter Top  Count  NTX;  Packard  Bioscience, 
Meriden, CT
2.3 Animals
BALB/c mice were obtained for the entire study. The animals were aged 6~8 weeks 
and  were  maintained  according  to  the  ARVO  Statement  for  Use  of  Animals  in 
Ophthalmic and Vision Research and according to the guidelines approved by the 
institutional animal care and use committee, and according to the Institutional Board 
(Genehmigung eines Versuchsvorhabens, nach § 8 Abs. 1 des Tierschutzgesetzes).
2.4 Virus
HSV-1 KOS strain was kindly provided by David Knipe (Harvard Medical School, 
Boston, MA). The virus was isolated and expanded on Vero cells (CCL 81; American 
Type  Tissue  Collection,  Manassas,  VA).  When  confluent  effects  appeared,  virus 
infected  vero  cell  monolayers  were  harvested.  After  three  times  freeze-thawed, 
homogenized and centrifuged, the virus-containing supernatants were collected. 
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2.5 Plaque assay
1 Dilute Vero cells (CCL 81: American Type Tissue Collection, Manassas, VA) to a 
density of 1.5×105 cells/ml with RPMI and 10% fetal calf serum
2 Transfer 0.5 ml of this cell suspension to each well and incubate for 24 hours
3 The homogenized virus-containing solution were 10 folds step diluted in RPMI 
medium as 10-1-10-8 
4 Discard  the  medium over  Vero  cells  and  add  0.2ml  of  diluted  virus  solution 
quickly
5 Standard virus suspension of 2×108PFU/ml was add as positive controls
6 RPMI medium was add as negative controls
7 Incubate for 1 hour at 37°C
8 Melt the agarose completely in a microwave being careful to allow air to escape to 
avoid exploding glassware
9 Mix 50ml agarose, 50 ml 2×RPMI and 1ml Ciprobay, keep in 35-37°C until use 
10 Remove the suspension in the wells  and cover well  with 0.7ml RPMI/agarose 
medium 
11 Place the plate in a 37°C, 98% humidity controlled incubator for at least 2-3 days
12 Incubate with 200μl 37% formalin solution to fixing the cell layers for 1 days
13 Discard the RPMI/agarose carefully in each well
14 Stain the cells with 200μl 2% crystal violet for 30 seconds
15 Wash with water and dry them
16 Count the plaques under microscope fields
17 The  titer  (PFU/ml)  may  be  calculated  by  the  following  formula:  PFU/ml  (of 
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original stock) = Counts×5×dilution factor (ml of inoculum/plate)            
2.6 Infection of the anterior chamber with HSV-1
The animals were anesthetized with ketamin (2mg) and mepivacaine hydrochloride 
(400ng) intraperitoneally. The AC of the right eyes were inoculated with 2x104 PFU 
of HSV-1 contained in a total volume of 5 µl PBS. The experiments were repeated to 
test the reproducibility of the results.
2.7 Injection technique into the vitreous
2µl ASON solution (100nMol) was injected into the vitreous of the left eyes by three-
direction tap system. Injections were performed using glass pipettes with a diameter 
of approximately 150µm at the tip made with a standard pipette puller. The pipette 
was connected to a three direction tap with a 10µl Hamilton syringe and a normal 
syringe.  ASON was stored in the normal  syringe.  Before injection,  2µl  of ASON 
solution were uploaded in the Hamilton syringe. The lid fissure was opened and the 
eye proptosed by gentle pressure on the temporal upper eyelid. Under an operation 
microscope, the eye was punctured directly at the pars plana, and the 2µl were then 
injected  into  the  vitreous  behind  the  lens.  Since  reflux  of  a  certain  amount  of 
intraocular fluid is unavoidable when removing the pipette from the injection site, the 
pipette was kept in place for 10 seconds to allow diffusion of the solution. 
2.8 Injection technique for subconjunctival injection
Mice  received  a  subconjunctival  injection  of  ASON  at  the  right  eye.  Under  an 
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operation microscope, the conjunctiva was elevated with an iris forceps, Bonn model 
(Geuder, Germany). 50 µl (2.5 µMol) of the ASON solution was injected into the 
conjunctiva  using  a  30-gauge  needle.  The  injection  resulted  in  a  circular  bleb 
formation around the corneal limbus.
2.9 Antisense oligonucleotides
ASON targeted to TNF-α and control oligonucleotides (CON) were designed and 
manufactured by Biognostik (Göttingen, Germany). For against enzymatic cleavage 
by DNases, the full-length backbone was modified. In these phosphorothioates one of 
the nonbridging oxygens of the phosphate backbone is replaced by a sulfur atom. This 
is achieved through postcoupling oxidation with a sulfurizing reagent (EDITH (3-
ethoxy-1,2,4-dithiazoline-5-one); PE Applied Biosystems, Weiterstadt, Germany). 
The ASON (CGA AGT TCA GTA GAC AG) used in the present study is the reverse 
complement to the bases 300 to 316 of the total sequence of murine TNF-α, and it 
targets an exon of the coding region. The mixed antisense oligonucleotides in a 
randomized fashion are obtained as the controls. Cross homologies with other genes 
were excluded for both sequences in the GenBank database 
(http://www.ncbi.nlm.nih.gov/Genbank; provided in the public domain by the 
National Center for Biotechnology Information, Bethesda, MD). ASON and CON 
(GCT CTA TGA CTC TTC AG) have identical chemical modification.
2.10 ASON in vitro uptake by lymphatic cells from the lymph nodes and spleen
Regional lymph nodes and spleens were harvested from HSV-infected mice at days 10 
PI  (Bauer  et  al.,  2002).  The  spleens  or  lymph  nodes  were  homogenized  and 
centrifugated at  1500 rpm for 10 min.  Single-cell  suspensions were prepared,  and 
20
cells were cultured in 96-well plates (1x105 cells/well). The culture medium contained 
RPMI,  5%FCS, HEPES and β-mercaptoethanol.  The cells  were treated with 2μM 
fluorescein  isothiocyanate  (FITC)-labeled  ASON from 15  minutes  to  48  hours  in 
dark, then washed 3 times by adding 150μl PBS and centrifuged 5 minutes at 1000 
rpm. All of the cells were separated in 2 groups for fluorescence microscopy and flow 
cytometry assay.
2.11 Fluorescence microscopy assay
1 50μl single-cell suspension was scattered on APES coated slides
2 Dry the slides in air at room temperature
3 Fix the cells in RPMI with 4% paraformaldehyde
4 Place the slides in graded ethanol series (70%, 80%, 96%, 100%) 2 minutes for 
dehydrating
5 Exam them under fluorescence microscopy in dark room
2.12 Flow cytometry assay
The flow cytometer (FacsCan BD) was calibrated by standard fluoresent beads before 
assay.  For each sample,  20,000 events were measured. Cells without FITC-ASON 
served as the negative control. The data was analysis with Facs Scan software.
2.13 Uptake of ASON in vivo
50μl  FITC-labeled  TNF-α-ASON  (50nMol/µl)  was  injected  subconjunctivally  in 
mouse. In another group, 2μl FITC-labeled TNF-α-ASON (50nMol/µl) was treated 
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with mouse by intraocular injection. The eyes were harvested after 1, 2， 3, 7 and 10 
days. Specimens were then dehydrated in ascending ethanol series, fixed in acetone, 
and embedded in paraffin. The specimens were then cut into 5µm sections and fixed 
on APES (3-aminopropyltriethoxysilane) covered slides. The distribution of the FITC-
positive staining was observed by fluorescence microscopy.
2.14 TNF-α expression in eyes
Animals were killed on day 8 PI. The left eyes were removed and snap frozen in 
liquid nitrogen. They were then thawed and homogenized by manual treatment. The 
supernatants were collected after centrifugation for TNF-α assay by standard ELISA 
(PharMingen, Heidelberg, Germany). 
2.15 Enzyme-linked immunosorbent assay
1 Coat microwells with 100 μL per well of capture antibody
2 Seal plate and incubate overnight at 4° C
3 Aspirate wells and wash 3 times with ≥ 300 μL/well PBS with 0.05% Tween-20
4 Block plates with ≥ 200 μL/well PBS with 10% FCS 
5 Incubate at room temperature for 1 hour
6 Aspirate wells and wash 3 times
7 Pipette 100 μL of each standard, sample, and control into appropriate wells
8 Seal plate and incubate for 2 hours at room temperature
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9 Aspirate wells and wash 5 times
10 Add 100 μL of detection antibody and HRP in each well
11 Seal plate and incubate for 1 hour at room temperature
12 Aspirate wells and wash 7 times
13 Add 100 μL of substrate solution containing tetramethylbenzidine and hydrogen 
peroxide to each well
14 Incubate plate (without plate sealer) for 30 minutes at room temperature in the 
dark
15 Add 50 μL of stop solution (1 M H3PO4 or 2 N H2SO4) to each well
16 Read absorbance at 450 nm within 30 minutes of stopping reaction
(Bauer et al., 2002).
2.16 Experimental Design
In all of the mice, HSV-1 solution was injected into the right eyes on day 0. The left 
eyes were treated on days –1, +1 and +4 with subconjunctival injections. The mice 
from group 1 (n=20) received 2.5μM of ASON in 50μL PBS. The mice from group 2 
(n=20) served as the control for substance-specific bystander effects and, therefore, 
received 2.5μM of CON in 50μL PBS. The mice from group 3 (n=20) were given 
50μL PBS.
2.17 Clinical Examination
Ipsilateral and contralateral eyes were examined every day with a binocular operation 
microscope. The development of intraocular inflammation, particularly contralateral 
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chorioretinitis,  was evaluated in a masked fashion. Anterior chamber inflammatory 
reaction,  papillary and iris  vessel dilation,  cataract  formation,  vitreal  haziness and 
whitening of fundus reflex were examined by two observers.
2.18 Histology
Animals were killed on day 8 and 10 after the HSV-1 was injected into anterior 
chamber. 
1 Remove the left eyes and fix for 6 hours in 4% formalin. 
2 For dehydrating, keep specimens in graded ethanol series (70%, 80%, 96%, 
100%,100%), each for 1.5 hours
3 Keep specimens in acetone for 1.5 hours twice
4 Keep specimens in xylol for 2 hours 
5 Keep specimens in paraffin three times for 1 hour at 60° C 
6 Embedded in paraffin 
7 Cut the tissue cross-sections into 5-μm thick. 
8 Fix the sections on the APES coated slides
9 For  deparaffination, keep the sections in xylol 10 minutes for 3 times   
10 For rehydrating, keep the sections in degrade ethanol series (100%, 100%,96%, 
80%, 70%), each for 3 minutes
11 Rinse in distilled water twice
12 Stain with hematoxylin for 30 seconds
13 Rinse in distill water twice
14 Stain in eosin for 30 seconds
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15 Rinse in 96% ethanol for 3 minutes 3 times
16 Rinse in 100% ethanol for 3 minutes 3 times
17 Rinse in xylol for 3 minutes 3 times 
18 Mount sections in eukitt and coverslips 
The infiltrating cells in ciliary body, retina and choroid were enumerated by means of 
brightfield microscopy under a 10×10 grid high-power (×250) (n=5/Group). 
The severity of retinitis was graded on a scale of 0 to 2+.
Grade 0: no retinitis present. 
Grade 1+: infiltrating inflammatory cells in the inner 1/3 of the retina, especially 
perivascularly. Foci of retinitis
Grade 2+: infiltrating inflammatory cells in the entire depth of the retina, involving at 
least half of retina.
2.19 Glass slide coating protocol
1 Place the precleaned slides in slide rack in the plastic slide box
2 Rinse slides in 96% ethanol 
3 Place slide rack into acetone in slide box for 2 minutes
4 Transfer slide rack into 2% APES in slide box for 20 seconds
5 Place slide rack into acetone for 2 minutes
6 Rinse slides in distilled water
7 Dry the slides in 80°C oven for 1 hour
2.20 Immunohistochemistry
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The eyes, regional lymph nodes or spleens were removed, snap frozen  in liquid 
nitrogen, and were kept at –70°C until use. The 5µm sections were prepared with a 
cryostat, and were fixed on the APES coated slides.
1 Dry sections on slides in the air at room temperature
2 For blocking the non-specific binding sites, incubate sections with 5% secondary 
antibody animal’s serum in PBS
3 Remove serum
4 Rat anti-mouse CD3, CD11b or F4/80 (Pharmingen, Germany) as the primary 
antibody were diluted to 1:50, 1:100, or 1:200 in PBS with 1% FCS 
5 Incubate sections with primary antibody at room temperature for 20 minutes
6 Replace the primary antibody by PBS in control sections
7 Incubate in 3% hydrogen peroxide for 5 minutes for blocking the endogenous 
peroxidase activity
8 Rinse sections with PBS 3 times
9 Biotinylated rabbit anti-mouse immunoglobulins (DAKO, A/S, Denmark) as the 
second antibody was diluted to 1:200 in PBS with 1% FCS
10 Incubate sections with the second antibody at room temperature for 20 minutes
11 Rinse sections with PBS 3 times
12 Incubate sections with peroxidase-conjugated streptavidin (1:500) (DAKO, A/S, 
Denmark) for 20 min 
13 Rinse sections with PBS 5 times
14 Mount sections in substrate
15 Observe under the microscope and stop after 10-15 minutes
16 Stop the reaction by 4% formalin in acetate buffer (pH5)
17 Rinse in 1% acetic acid 
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18 Stain with hematoxylin for 15 seconds
19 Mount with aquatex and cover with glass coverslip
2.21 Delayed-Type Hypersensitivity Reaction
Ten days following virus inoculation, mice were received in right footpad with 1×107 
PFU HSV-1 in 50μl RPMI, and in the left footpad with 50μl RPMI. Footpad thickness 
was measured 24 hours later with a micrometer. The difference between the swelling 
in left and right footpads was calculated as the HSV-1-specific DTH.
2.22 Detection of Virus titer in the Eye
Virus titer was studied with a plaque assay, as reported previously (Bauer et al., 2001). 
Whole eyes were collected and were snap frozen in liquid nitrogen on days 10 PI. The 
HSV-infected tissue specimens were thawed and homogenized. After centrifugation at 
2000rpm for 20 min to remove the cell debris, the supernatant of each sample was 
serially diluted. The samples were cultured on Vero cell monolayers. After 1 hour of 
incubation at 37°C, the supernatants were discarded. Each well was covered with 
RPMI-agarose medium and incubated in a 5% CO2 atmosphere at 37°C for 2 to 3 
days. The cells were fixed with 37% buffered formalin and stained with 2% crystal 
violet, and the plaques were counted (respective details described in section “Plaque 
assay”).
2.23 Proliferation Assay with [3H]thymidine
1  The left regional lymph node were homogenized and a single cell suspension was 
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prepared (1x106 cell/ml).The cells were cultured in 96-well plates for 3 days at a 
density of 1×105 cells in 100μl medium per well.
2  Add 2μl UV-inactivated HSV (2×106 PFU before inactivation per well) into wells 
directly.
3  Add 2μl ConA (0.5μg/ml) into wells as the positive controls.
4  Add 2μl 10% FCS into wells as the negative controls
5  All of the cells treated with different stimulants were cultured for 3 day at 37°C 
6  1μCi of [3H]thymidine were incubated with cells for 24 hours
7  Spot lysates on a glass filter with a cell harvester and wash out unincorporated 
[3H]thymidine with sterile water
8  Determine radioactivity in a scintillation counter
 (Bauer et al., 2002)
2.24 Statistical analysis
Unpaired two-tail Student’s t-test was used to determine the significance of the 
differences in number of cells in the eye, retinitis grade, DTH, ELISA, plaque assay 
and proliferation assays. Fisher’s test was used for statistical analysis of the difference 
in the incidence of retinitis. P<0.05 was considered statistically significant.
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3. Results
3.1 ASON uptake in vitro
To study the uptake of FITC-ASON in vitro, regional lymph nodes and spleens were 
harvested from HSV-infected mice and single-cell suspensions were collected. The 
cells  were  cultured  with  FITC-labeled  ASON  (2μM/L)  and  examined  under 
fluorescence microscopy or flow cytometry. After 15 minutes, the fluorescence was 
easily detectable in the cells. The maximum of fluorescence was observed between 8 
and 12 hours of incubation (95% fluorescence positive cells). Even 48 hours later, it 
was still detectable in the cultured cells. (Fig 4)
Flow cytometric analysis disclosed that more than 67% of the lymph node cells were 
fluorescence positive after incubating them with FITC-ASON for 15 minutes. There 
were still  fluorescence positive cells  after  48 hours of incubation (Fig 5).  Similar 
results were found in both lymph node and spleen cells.
3.2 Subconjunctival Injection of ASON
3.2.1 ASON uptake in vivo
To study the uptake of ASON in vivo mice were treated with a single subconjunctival 
injection  of  50μl  FITC-labeled  TNF-α-ASON,  and  were  then  enucleated  after 
different  time-points.  Sections  from  the  eyes  were  studied  with  a  fluorescence 
microscope. On day 1 after the injection, the sclera and subconjunctival tissue were 
strongly fluorescent positive. In addition, the fluorescent staining was also found in 
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the choroid, in the retinal vessels and few cells within the retina, which are most 
probably the Müller cells (Fig 6). This staining pattern was not markedly different on 
day 2 PI. FITC-TNF-α-ASON was detected in the choroid and retinal vessels up to 7 
days after injection, but the staining was less intense. A few cells in lymph node were 
stained positively just on day 1 PI (Fig 6). In contrastingly, intracellular fluorescence 
was undetectable in the spleen.
3.2.2 TNF-α-ASON reduced the TNF-α expression in vivo
To study the TNF-α-expression after injection of ASON eyes were infection with 2μl 
HSV. TNF-α-ASON, CON or PBS was injected subconjunctivally on the days -1, +1 
and +4. The eyes were harvested on day 8 PI. The cytokine expression in the eye was 
measured by an ELISA technique. The levels of TNF-α in the eye were markedly 
diminished after subconjunctival injection with TNF-α-ASON compared with other 
groups.  Otherwise,  the  TNF-α  level  in  the  PBS  and  CON  groups  were  not 
significantly different (Fig 7).
3.2.3 Clinical course of the retinitis on day 8 PI in the contralateral eyes after 
administration of TNF-α-ASON 
Inflammatory cell infiltration in the contralateral eye in the v. Szily model can be 
found  after  7-8  days  PI.  The  following  tests  were  done  to  determine,  if  the 
administration of ASON would be able to decrease the incidence or severity of ARN. 
For the induction of the disease, the right eyes were injected with HSV-1. The TNF-α-
ASON, CON or PBS was injected subconjunctivally on the days -1, +1 and +4. The 
eyes were harvested on day 8 PI. 
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Fig 8 shows the incidence of contralateral retinitis in the different treatment groups. In 
the PBS treatment group, 6 out of 12 mice (50%) had developed clinical signs of 
contralateral retinitis by day 8. The CON treatment group had a similar incidence (7 
out of 14, 50%) of contralateral retinitis. In contrast, after TNF-α-ASON treatment, 
only 2 out of the 14 mice (14.29%) had developed retinitis by day 8 (P<0.05). 
3.2.4  Histological  findings  in  the  contralateral  eyes  on  day  8  PI  after 
administration of TNF-α-ASON 
Eye specimens were analyzed histologically to determine if the clinical findings could 
also be found in the eye specimens obtained from the animals.
By day 8 PI, there was a severe acute retinitis in the left eyes in the mice from the 
PBS and CON treatment group. Photoreceptor layer collapse and outer nuclear layer 
disruption was seen in the retina. The inflammatory cell infiltration varied between 
the individual mice. While retinitis was focal in some mice, it  involved the entire 
retina in others. Vitritis was present in all mice from these 2 groups. The underlying 
choroid had a profound inflammatory cell infiltration in all mice.
In contrast, TNF-α-ASON treated mice had only a mild retinitis. It was typically focal 
and involved only the inner 1/3 of the retinal layers. The retinal structure was still 
well organized, and contained a quite small number of inflammatory cells, primarily 
polymorphonuclear leukocytes (PMN) and lymphocytes. Only few inflammatory cells 
were found in the vitreous (Fig 9).
In order to quantify the severity of contralateral retinitis, the inflammatory cells in 
retina  were  enumerated.  The  healthy  retina  contains  ganglion  cells,  Müller  cells, 
photoreceptor cells and others. The inflamed retina contains additional inflammatory 
cells. 
The infiltrating inflammatory cells cannot be clearly distinguished from the retinal 
cells in the inflamed retina. Therefore, the total number of cells was enumerated, and 
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the mean number of cells that are generally present in healthy retina was subtracted in 
order to determine the number of inflammatory cells. However, the number of cells 
counted in the highly inflamed retina may be mistakenly too low,  as retinal  cells 
damaged by inflammation might have been remove by phagocytes.
In order to quantify the severity of contralateral retinitis, the inflammatory cells in 
retina were enumerated in the technique described above. The mean retinitis severity 
was 0.76 in TNF-α-ASON group, and was 1.50 in the PBS and 1.56 in the CON 
group. The severity of retinitis in animals treated with TNF-α-ASON was markedly 
reduced as compared to the other groups (P<0.05) (Fig 10).
Furthermore, the inflammatory cell infiltration in the ciliary body and choroid were 
determined on day 8. While the ciliary body and choroid was highly infiltrated by 
inflammatory cells both in the PBS and CON treated mice, only a mild inflammation 
was seen in the TNF-α-ASON treated group. The number of inflammatory cells in 
ciliary body in mice that were treated with PBS was significantly higher (P<0.05) 
than TNF-α-ASON (29.96±30.52 vs. 7.48±9.52). Correspondingly, the choroid from 
the mice that were treated with TNF-α-ASON had also significantly fewer (P<0.05) 
inflammatory cells than in the PBS (28.14±31.44 vs. 75.33±75.78) (Fig 11).
3.2.5 Immunohistochemical studies of the contralateral eyes on day 8 PI after 
administration of TNF-α-ASON 
To examine the cell  populations in  the ASON treated eyes,  immunohistochemical 
stainings against the cell marker CD11b, CD3, F4/80, or IA/IE were performed.
1  CD11b
Large numbers of CD11b positive cells were observed in the retina and choroid of 
mice from the PBS group and CON group (Fig 12). The positive cells were mainly 
found in the ganglion cell layer and inner plexiform layer of retina, in the ciliary body 
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and choroid. In the retina of mice from the TNF-α-ASON treatment group, only few 
CD11b positive cells were found in the retina, choroid and ciliary body.
The numbers of CD11b cells found in the 3 experimental groups are summarized in 
figure 13. The number of CD11b positive cells in the ciliary body was reduced in the 
TNF-α-ASON treated group as compared to the CON and PBS groups, the difference 
did not reach the level of significance. Compared with the PBS and CON treatment 
group, the infiltration with CD11b positive cells in contralateral retina and choroid of 
the TNF-α-ASON treated mice was significantly reduced (P<0.05).  
2 CD3
The CD3 positive cells were found in PBS group and CON group predominantly in 
the choroid and ciliary body(Fig 14). In the TNF-α-ASON treatment group, only few 
such cells were found in the choroid. In the 3 groups of mice, no significant CD3 cell 
numbers were found in the retina.
Following TNF-α-ASON treatment, the number of CD3 positive cells in ciliary body 
decreased significantly as compared to the control group (P<0.05). Compared with the 
PBS treated group, the number of positively stained cells in choroid from the TNF-α-
ASON treated mice was reduced. However, due to the small numbers of cells found in 
all  of  the  groups  and  tissue  areas,  the  differences  did  not  reach  the  level  of 
significance (Fig 15). 
3 F4/80
F4/80 positive cells were found in the eyes from the PBS group (Fig 16). Most of the 
F4/80 positive cells were located in ciliary body, choroid, and in the inner nuclear and 
ganglion  cell  layers  of  the  retina.  In  the  TNF-α-ASON group,  only  a  few F4/80 
positive cells were found in the choroid.
Compared with the mice of the PBS treatment group, there was the tendency that the 
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cellular infiltration with F4/80+ cells in retina with TNF-α-ASON and CON treatment 
was reduced. In general, only few such cells were found in the eyes of the mice from 
the 3 experimental groups (Fig 17).
4 IA/IE
IA/IE positive cells were observed in PBS and CON group (Fig 18). The positive cells 
were mainly found in the ciliary body and choroid. The retina had a faint and diffuse 
positive staining with this antibody. In the mice from the TNF-α-ASON treatment 
group, no IA/IE positive cells were found in the retina, and only few IA/IE positive 
cells were detected in the choroid.
Compared with the PBS treatment group, the number of IA/IE positive cells in the 
ciliary body was reduced in the TNF-α-ASON and CON treatment (P<0.05). No such 
cells were found in the retina in all three groups. In the choroid, the number of  IA/IE-
positive  cells  was  lower  in  the  TNF-α-ASON group  than  in  the  other  2  groups, 
however, the difference did not reach the level of significance (Fig 19).
3.2.6 Clinical course of retinitis on day 10 PI in the contralateral eyes after 
administration of TNF-α-ASON 
The following tests were performed to determine if the ASON-treatment of mice with 
ARN could be used as a therapeutic treatment option. 
Fig  20  summarizes  the  incidence  of  contralateral  retinitis  following  the  different 
treatment regiments. In the PBS treatment group, 9 of 12 mice (75%) had developed 
clinical  signs  of  contralateral  retinitis  by day  10.  In  the  CON treatment  group,  a 
similar incidence of contralateral retinitis was found (8 of 11, 72.7%). And after TNF-
α-ASON treatment, 11 of 14 mice (78.6%) had developed retinitis by day 10 PI. The 
difference  in  the  incidence  of  retinitis  in  the  contralateral  eyes  between  TNF-α-
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ASON-treated  mice  and  control  groups  was  not  significant  (P>0.05).  Retinitis 
included  severe  vitreous  opacity,  retinal  veins  dilated  and  tortuous.  Tractional 
detachment of the retina was a prominent clinical feature.  
3.2.7 Histological findings of retinitis on day 10 PI in the contralateral eyes after 
administration of TNF-α-ASON 
In order to further analyze the effect of TNF-α-ASON treatment on the course of 
contralateral inflammation, we studied the histological findings on day 10 PI. Retinal 
necrosis was typically detected in the PBS, CON and TNF-α-ASON treatment group. 
Compared with the findings on day 8 PI, the inflammation was now more severe in all 
of the three groups. In addition, large areas of retinal necrosis were noted, and 
vasculitis, perivasculitis, vascular occlusions and fibrin deposition were prominent. 
The ganglion cell layer, inner and outer nuclear layers were disarranged. The 
inflammatory infiltrate, containing mainly PMN, but also monocytes and 
lymphocytes, now involved the entire depth of the retina. The choroid underlying the 
necrotic area was also heavily infiltrated with inflammatory cells. Inflammatory cells, 
phagocytes and necrotic cell particles were found in the vitreous. (Fig 21). Tractional 
retinal detachment was noted. No obvious difference in the histopathological 
appearance was obvious between the 3 treatment groups.
3.2.8 Immunohistochemical studies of the contralateral eyes on day 10 PI after 
administration of TNF-α-ASON 
1  CD11b
Many CD11b positive cells were observed in PBS, CON and TNF-α-ASON group 
(Fig 22). The positive cells were mainly found in retina, ciliary body and choroid. The 
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CD11b positive cell numbers in posterior segment on day 10 PI were increased when 
compared to the observations on day 8 PI. Similar to both of the control groups, the 
numbers of CB11b+ cells in the retina and choroid were reduced in the TNF-α-ASON 
group.
As shown in Fig 23, many CD11b positive cells were observed in ciliary body, retina 
and choroid on day 10 PI. In ciliary body, the number of CD11b positive cells in TNF-
α-ASON treated group was smaller than in the CON group, but the difference did not 
reach the level of significance. Compared with the PBS and CON treatment groups, 
the  number  of  CD11b+ cells  in  contralateral  retina  and choroid  was  significantly 
decreased in the TNF-α-ASON treatment group (P<0.05). 
2  CD3
A large number of CD3 positive cells was noted in the PBS, CON and TNF-α-ASON 
groups (Fig 24). The positive cells were located in ciliary body and choroid, and some 
CD3+ cells were also located in the retina. Compared with the immunohistochemical 
findings on day 8 PI, the number of CD3+ cells infiltrating the ciliary body, choroid 
and retina were increased (P<0.05).
As shown in Fig 25, the CD3 positive cells were observed in ciliary body, retina and 
choroid on day 10 PI. With TNF-α-ASON treatment, the positive cell number in retina 
was significantly  lower  than in  the  PBS and CON group (P<0.05).  However,  the 
number of CD3+ cells  in the ciliary body and choroid did not differ  between the 
treatment groups. 
Taken together, the total number of infiltrating cells increased between day 8 and 10 
PI, and this was associated with an increased number of CD3+ cells.
3 F4/80
Many F4/80 positive cells were found in the PBS and CON group (Fig 26). Most of 
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the positive cells were located in choroid and retina. Only a few F4/80 positive cells 
were observed in ciliary body. In the TNF-α-ASON group, few positive cells were 
observed in contralateral posterior segment. 
Compared with the immunohistochemical findings on day 8 PI, the number of F4/80+ 
cells was increased in the retina from the contralateral eyes on day 10 PI, while the 
F4/80+ cell numbers were not changed in the ciliary body and choroid. Compared 
with PBS and CON treatment groups, the cellular infiltration in the retina and choroid 
from the TNF-α-ASON treatment group was suppressed significantly (P<0.05) (Fig 
27).
As the numbers of infiltrating CD11b cells in the choroid and retina of the TNF-α-
ASON treated mice are higher than the numbers of F4/80+ cells, it may be concluded, 
that the infiltrating CD11b+ cells are not macrophages but primarily PMN.
4 IA/IE
The IA/IE positive cells were found primarily in the ciliary body and in the choroid, 
but some IA/IE cells were also found in the necrotic retina. The immunohistochemical 
appearance did not profoundly differ between the mice in the PBS, CON and TNF-α-
ASON groups (Fig 28). 
The numbers of IA/IE + cells in the contralateral  eyes did not differ significantly 
between the three groups. Compared to the findings on day 8 PI, the numbers of 
IA/IE+ cell  were slightly increased on day 10 PI, however, the difference did not 
reach the level of significance (Fig 29).
3.2.9 Delayed-type hypersensitivity reaction on day 10 PI after administration of 
TNF-α-ASON 
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As shown in Fig 30, the HSV-1 specific DTH response did not differ significantly 
between mice that received PBS, CON or TNF-α-ASON (P>0.05).
3.2.10  T  cell  proliferation  assay  with  [3H]thymidine  on  day  10  PI  after 
administration of TNF-α-ASON 
To evaluate the effect of  TNF-α-ASON on the systemic immune response against 
HSV-1, the antigen specific proliferation of lymphocytes obtained from the regional 
lymph nodes was detected on day 10 PI. As shown in Fig 31, the HSV-1 specific T 
cell response was lower in the mice after TNF-α-ASON treatment as compared to the 
PBS and CON treated groups (P<0.05) (Fig 31).
3.2.11 Virus titer in eyes on day 10 after administration of TNF-α-ASON
 
As the clinical and histological findings revealed an acceleration of herpetic retinitis 
between the day 8 and 10 PI, we wondered whether this might be associated with an 
increased virus titer at this time point. The PFU content was studied with a standard 
plaque assay. The results show that virus titers were increased in the TNF-α-ASON 
treatment group as compared to the PBS and CON group of mice (Fig 32, P<0.05). 
3.3 Intraocular Injection of TNF-α-ASON
3.3.1 ASON uptake in vivo
The mice were treated with a single intraocular injection of 2μl FITC-labeled TNF-α-
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ASON, and were then enucleated after different time points. Sections from the eyes 
were studied with a fluorescence microscope. On day 1 after the injection, the corneal 
endothelium,  iris,  ciliary body,  vessels  of  retina,  ganglion cells  and choroid were 
strongly  fluorescent  positive  (Fig  33).  This  staining  pattern  was  not  markedly 
different on day 2 PI. However, on day 2, the staining in the endothelium was absent 
already, and the staining was less intense in the iris, ciliary body, choroid and retina. 
While the inner ganglion cells were still fluorescent positive, the nuclear layer was 
negative  for  the  FITC  staining.  On  day  3  after  injection,  only  a  staining  of  the 
ganglion  cells  was  present,  while  the  other  tissues  were  fluorescent  negative.  No 
positive staining was detected after 7 days.
It was, therefore, concluded that the injections should either be repeated at least every 
3  days.  For  the  first  set  of  experiments,  the  injections  were  planed  for  the  first 
experiments  on  the  days  –1,  +1,  and  +4  PI,  as  the  up-regulation  of  TNF-α  was 
detected in previous experiments by 6 to 8 days PI, and before the onset on retinitis. 
Also, the regional lymph nodes and spleen were removed after 1 and 3 days and were 
studied  by  fluorescence  microscopy.  TNF-α  was  not  detected  in  the  samples  at 
different time point (Fig 33).
3.3.2 TNF-α-ASON reduced the TNF-α expression in vivo
The right eyes of the mice were infected intraocularly with 2μl HSV, and TNF-α-
ASON, CON or PBS was injected into the vitreous cavity of the left eyes on the days 
-1, +1 and +4. The left eyes were harvested on day 8 PI. The cytokine expression in 
the eye was measured by an ELISA technique. The levels of TNF-α in the eye were 
markedly  diminished  after  treatment  with  TNF-α-ASON  as  compared  with  other 
groups. Otherwise, the TNF-α level in PBS and CON groups showed no significant 
differences (Fig 34). 
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3.3.3  Clinical  course  of  retinitis  on  day  8  PI  in  the  contralateral  eyes  after 
administration of TNF-α-ASON 
The viral retinitis was induced by intracameral injection of the right eyes with HSV-1. 
In order to modify the course of the disease in the contralateral eyes, TNF-α-ASON 
was injected into the vitreous cavity of the left eyes. CON or PBS was injected in the 
mice of the control groups. The eyes were injected 3 times (days -1, 1 and 4 PI) and 
were then harvested on day 8 PI. 
Fig 35 shows the incidence of contralateral retinitis following the treatment in the 
three experimental groups. In the PBS treatment group, 10 of 18 mice (55%) had 
developed clinical signs of contralateral retinitis by day 8. The CON treatment group 
showed a lower incidence of contralateral retinitis. After TNF-α-ASON treatment, 7 
of 17 mice (41.18%) had developed retinitis by day 8 PI. No significant differences 
were found between the groups.
It was obvious that some of the mice developed a retinal detachment after the repeated 
injections. This untoward side effect from the injection occurred following the second 
or third injections in approximately 2 out of 3 animals. Retinal detachment was the 
most frequent side effect observed in PBS (11 of 18 animals), CON (10 of 15) and 
TNF-α-ASON (12 of  17)  group.  This  suggested that  repeated injections  might  be 
followed  by  severe  complications  that  are  related  to  the  injection  method.  In 
conclusion, single injections at a critical time-point directly before the up-regulation 
of the HSV-1 induced TNF-α peak in the contralateral eyes might be superior to the 
repeated injection regiment used herein.
3.3.4  Histological  findings  in  the  contralateral  eyes  on  day  8  PI  after 
administration of TNF-α-ASON 
By day 8 PI, there was an acute retinitis in the left eyes in the mice from the PBS, 
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CON  and  TNF-α-ASON  treatment  group.  Photoreceptor  layer  collapse  and  outer 
nuclear layer disruption was seen in the retina.  The inflammatory cell  infiltration, 
however, varied considerably between the individual mice. In some mice, the retinitis 
was focal and involved only the inner 1/3 of the retinal layers. The retinal structure 
was  still  well  organized,  and  contained  a  small  number  of  inflammatory  cells, 
primarily PMN and other leukocytes. A few inflammatory cells were found in the 
vitreous  (Fig  36).  The  retinitis  involved  the  entire  retina  in  other  mice.  In  sharp 
contrast, some of the mice did not have any contralateral retinitis. Vitritis was present 
in all mice from these 2 groups. The underlying choroid had a marked inflammatory 
cell infiltration in all mice.
In order to quantify the severity of contralateral retinitis, the inflammatory cells in the 
retina were enumerated in the technique described above. The mean retinitis severity 
was 1.25 in TNF-α-ASON group, and was 1.0 in the PBS and CON group (Fig 37). 
The difference was not significant (P>0.05).
Also, the inflammation of the ciliary body and choroid varied considerably between 
the individual mice.  A heavy infiltration by inflammatory cells  was seen in  some 
mice, while only a mild inflammation was seen in other groups. The ciliary body and 
choroid was highly infiltrated by inflammatory cells both in the PBS and TNF-α-
ASON treated mice. The numbers of inflammatory cells in ciliary body in mice that 
were  treated  with  PBS  and  TNF-α-ASON  were  not  significantly  different 
(75.96±16.09 vs. 66.68±15.78, P>0.05). Correspondingly, the choroid from the mice 
that  were  treated  with  PBS  and  TNF-α-ASON  had  similar  inflammatory  cells 
(145.87±32.65 vs. 124.86±30.22, P>0.05) (Fig 38).  
Frank retinal detachment and proliferative vitreoretinopathy adjacent to the areas of 
scleral puncture was noted in some of the mice. This supports the clinical observation 
of this complication that is resulting from the injection technique. 
3.3.5  Clinical  course  of  retinitis  on  day 10  PI  in  the  contralateral  eyes  after 
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administration of TNF-α-ASON 
The Fig 39 summarizes the clinical findings that were obtained in the 3 groups at day 
10 PI. A considerable number of animals developed the typical signs of contralateral 
retinitis.  Compared with the PBS and CON treatment group, the retinitis rate was 
reduced in the TNF-α-ASON group. However, the difference between the groups did 
not reach the level of significance.
As noted already on day 8 PI, a great number of mice showed the typical signs of 
retinal detachment. 
3.3.6 Delayed-type hypersensitivity reaction on day 10 PI after administration of 
TNF-α-ASON 
As shown in Fig 40,  compared with mice that received PBS treatment, those that 
received TNF-α-ASON had a significantly reduced DTH reaction (P<0.05).
3.3.7  T  cell  proliferation  assay  with  [3H]thymidine  on  day  10  PI  after 
administration of TNF-α-ASON 
As shown in Fig 41, the HSV-1 specific proliferative response of cells obtained from 
the regional lymph nodes was significantly reduced both with CON and with TNF-α-
ASON treatment as compared to the PBS treatment. 
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4. Discussion
4.1 Background of the study
Previously it has been shown that TNF-α-mRNA and -protein was upregulated during 
the progression of ARN (from day 6 to 14 PI) in HSV-1 infected contralateral eyes 
(Zheng  et  al.,  2005).  The  TNF/TNF-R  family  plays  a  particular  key  role  in  the 
activation,  differentiation  and  effector  responses  of  T-cells.  As  TNF-α  plays  an 
important  part  in  the  development  of  ARN,  the  elimination  of  TNF-α-may  be 
candidate therapeutic approach. 
4.2 Alternative: systemic TNF-α inhibition
4.2.1 Disadvantages:
There are  several  possible  ways of  blocking TNF-α functions  in  vivo.  Etanercept 
(Enbrel®) is a soluble TNF-receptor-immunogobuline-fusion-protein. Soluble TNF-
receptors  can  bind  and inactivate  the  soluble  TNF-α.  Infliximab is  a  monoclonal 
chimeric  mouse-human antibody that  is  binding  with  high  affinity  to  soluble  and 
transmembranaous  forms  of  TNF-α.  In  vivo,  infliximab  quickly  builds  up  stable 
complexes  with  human  TNF-α.  Adalimumab  is  a  monoclonal  human  anti-TNF-
antibody. 
The  administration  of  all  of  the  commercially  available  TNF-α  inhibitors  by 
antibodies may be complicated by the development of humoral immune responses 
directed against the therapeutic antibodies after repeated application. Hypersensitivity 
reactions and severe infusion reactions especially when using the chimeric antibody 
of  infliximab may occur. In addition,  antibody production directed against  TNF-α 
might be associated with reduced treatment effects.
In addition, systemic treatment with TNF-α inhibitors resulted in an increased rate of 
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tuberculosis. Previously, it has been reported that 70 out of 12,100 patients that were 
under  therapy  with  Infliximab  developed  tuberculosis.  Until  2001,  12  cases  of 
tuberculosis  out of 117,000 patients treated with etanercept were reported (Keane, 
2001; Wallis et al., 2001; Reimold, 2003). In some patients, the development of auto-
antibodies has also been noted, and especially antinuclear antibodies or antibodies 
against ds-DNA, but also a lupus-like syndrome appeared. In 17 patients treated with 
etanercept and in another 2 patients treated with infliximab, demyelinating disease 
could  be  observed  (Mohan  et  al.,  2001).  Infliximab  led  to  the  aggravation  of 
moderately or severe heart insufficiency. The FDA Arthritis Drug Advisory Commitee 
reported about 16 infliximab patients and 19 etanercept patients with lymphomas. The 
follow-up period is yet too short to assess the long-term-risk of TNF-alpha inhibitors 
with  a  certain  accuracy.  In  addition,  antibody  production  directed  against  TNF-α 
might be associated with reduced treatment effects.
4.2.2 Advantages:
While side effects from systemic TNF-α inhibition might be untoward, modulation of 
the general immune response against HSV-1 may be of importance to the alteration of 
the course of acute contralateral HSV-1 retinitis. 
Previous  experiments  in  experimental  autoimmune  uveitis  have  revealed 
contradictionary results about the role of TNF-α in the development of uveitis. There 
has been profound evidence that TNF-α inhibition may lead to an improvement of 
EAU (Robertson et al,. 2003). However, TNF-α application has also been associated 
with an improvement of uveitis. 
There are several  lines of evidence that TNF-α participates in the pathogenesis of 
contralateral HSV-1 retinitis.  1. TNF-α expression is increased in the contralateral 
eyes during the development of acute HSV-1 retinitis. 2. The inhibition of TNF-α led 
to  an  improvement  of  acute  retinitis.  However,  the  role  of  TNF-α in  the  diverse 
compartments of the body, e.g in the eye, draining lymph node and spleen, and within 
44
the different cell types in the diverse compartment of the body, have not been defined 
in detail. As a consequent, it cannot be completely excluded, that TNF-α inhibition 
may  also  be  associated  with  a  worsening  of  the  course  of  experimental  HSV-1 
retinitis.
4.3 Cells and soluble factors in regional lymph node
It has been previously shown that cells in the regional lymph nodes are of critical 
importance for the antigen presentation. The cells in the regional lymph nodes may 
also be of importance for the course of experimental ARN. 
We intended to design a topical TNF-α inhibition in our experiments. However, we 
observed that FITC-positive cells were present in the regional lymph nodes after 
subconjunctival injection. The FITC-TNF-α-ASON was detected in the regional 
lymph nodes on the first day after subconjunctival injection. This drainage of dye to 
the regional lymph nodes is not unexpected, as the subconjunctival space is drained 
via the lymphatic system to the submandibular lymph nodes. Also, the secretion of 
TNF-α was reduced in lymphocytes obtained from the regional lymph nodes. We can 
only speculate about the relevance of this observation on the course of acute retinitis. 
It might be speculated that TNF-α expression is also decreased in the antigen 
presenting cells. Indeed, nearly 95% of the cells from the rLN were FITC positive, 
and this was true for small lymphocytes as well as larger phagocytes. As a 
consequence, early activated dendritic cells may be of relevance to the improvement 
of Th-1 induced disease in the retina. 
4.4 Cells and soluble factors in the spleen
It has been previously shown that cells in the spleen are of critical importance for 
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ACAID. Furthermore,  ACAID has been suggested to be critical  for the course of 
acute retinitis. Interestingly, fluorescent positive cells were not found in the spleen 
after subconjunctival FITC-TNF-α-ASON injection. It may, therefore, be speculated 
that cells or soluble factors that are critical for the course of acute retinitis may not be 
influenced by the subconjunctival treatment in the spleen.
4.5 Antisense oligonucleotides
In  principle,  there  are  several  action  mechanisms  of  ASON.  Beside  a  sequence 
specific activity from a binding to target mRNA, ASON can bind to other factors and 
they exert sequence unspecific interactions.
Antisense oligonucleotides have great therapeutic potential because of their ability to 
inhibit  the  synthesis  of  specific  proteins.  The  discovery  that  complementary 
nucleotide bases synthesized in 12-25 mer sequences can bind with specific mRNA 
synthesized to produce unique proteins, such as cytokines, in response to regulatory 
physiologic  stimuli  has  enormous  potential  to  alter  the  inflammatory  response 
(Agrawal & Kandimalla, 2000; Scanoon, 2004). The covalent hydrogen binding of 
antisense compounds to mRNA can effectively prohibit translation of specific mRNA. 
The construction of antisense oligonucleotides may be useful for the prevention of 
individual protein synthesis, thus permitting a wide variety of potential therapeutic 
application.
4.5.1 TNF-α-ASON for the treatment of inflammatory disease
ASON targeting  TNF-α has  been  used  to  treat  immune mediated disease  such as 
allergy,  Crohn’s disease (van Hogezand & Verspaget, 1998; Popescu et  al.,  2005). 
Wasmuth reported that topical treatment with TNF-α-ASON can reduced the severity 
of HSK (Wasmuth et al., 2003).
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4.5.2 Use of ASON in eye diseases
Inhibition  of  gene  expression  with  ASON  has  been  previously  applied  for  the 
treatment of some ocular diseases. Henry reported that fomivirsen (Vitravene, also 
known as ISIS 2922; Isis Pharmaceuticals, inc., Carlsbad, CA) which was designed to 
inhibit human CMV was approved for treatment of CMV retinitis (Henry et al., 2001). 
An ASON against vascular endothelial growth factor was delivered to the retina via 
intravitreal injection reduced iris neovascularization in monkey models (Bhisitkul et 
al., 2005). 
4.5.3 Uptake
It was indicated that the FITC-labeled ASON were taken up after 15 minutes in vitro 
by cells taken from the regional lymph node and spleen. It was still detectable in the 
cultured cells even 48 hours later. 
The ASON are taken up by nearly 95% of the cells ion vitro. The larger cells are most 
likely macrophages / monocytes. Cells with granular nuclei  are neutrophils.  Small 
cells were most likely lymphocytes. As described in the literature, TNF-α secretion is 
reduced in the T cell line H2T2 as in the macrophage cell line (Taylor et al., 1997)
As  epithelial  barriers  are  bypassed  by  subconjunctival  and  intraocular  injections, 
uptake enhances have not  been applied for  our  experiments.  When treated with a 
single subconjunctival injection, the intracellular fluorescence staining was found in 
the eye tissue such as choroid, retinal vessels and few cells within retina (most likely 
Müller cells) till on day 2PI. Although the staining was less intense, FITC-TNF-α-
ASON was still detected in the choroid and retinal vessels up to 7 days after injection. 
Transscleral  delivery  has  been  considered  to  be  an  alternative  for  the  intraocular 
delivery of macromolecules, because sclera has a large and accessible surface area, a 
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high degree of hydration rendering it conducive to water-soluble substances, and a 
hypocellularity with an attendant paucity of proteolytic enzymes and protein-binding 
sites.  It  appears  that  transscleral  influx  and  intrachoroidal  dispersion  of 
macromolecules in the mouse eye is not precluded by either transscleral aqueous flow 
or by choroidal blood flow (Kim et al., 2002). The fluorescence in the retinal vessels 
indicated that the hematogenous pathway may have also contributed to the intraocular 
dispersion of FITC-TNF-α-ASON. Most probably it penetrated the arterial wall in the 
retrobulbar region and mixed with the blood stream as the blood was about to enter 
the retina.
As compared with the recent findings in the cornea (Wasmuth et al., 2003), the uptake 
of  FITC-TNF-α-ASON in  the  retinal  tissue and uvea  was not  as  stable  as  in  the 
cornea. The long presence of ASON in the cornea might be related to the slow tissue 
turn over and metabolism in the cornea. The axoplasmatic transport mechanisms, the 
transport  in  the vessels  and in  the uvea might  have caused the faster  decrease of 
fluorescence.
The staining pattern of most of the cells suggests that the FITC-ASON is incorporated 
not only into the cell membrane, but also into the cytoplasm. 
Previously,  a  relation  between  the  uptake  of  ASON  and  cell  activity  has  been 
suggested (Zhao et al., 1996). Although no such studies were performed herein, we 
have seen that FITC-ASON was taken up into the eye. 
4.5.4 Toxicity
The concentration of the TNF-α-ASON solution was used as designed in our previous 
experiments in the HSK model (Wasmuth et al., 2003). As no toxic effects were noted 
in the treated eyes in the previous studies, a similar dye was applied for our present 
experiments.  Accordingly,  toxic  effects  to  the  treated  ocular  tissues,  by  means of 
clinical nor histological methods, have not been seen from the control ASON used in 
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our  studies.  Additionally,  no systemic  side effects  were noted in  any of  the mice 
treated in our experiments.
4.5.5 Stabilization against enzymatic cleavage
One of  the most  difficult  challenges  facing the anti-gene  field  is  ASON that  will 
stabilize, transducer and express a transgene in the target tissue. As described in the 
Methods, the TNF-α-ASON we used was modified to protect it  against  enzymatic 
cleavage by DNases. 
4.5.6 Decreased TNF-α protein expression after TNF-α-ASON treatment
It  was  reported  that  TNF-α-ASON  down-regulated  the  TNF-α  protein  in  vitro 
(Wasmuth  et  al.,  2003).  Furthermore,  the  secretion  of  TNF-α  in  the  cornea  was 
significantly  impaired after  ASON treatment  given three times in  vivo (Wasmuth, 
2003).  In  our  study,  when  the  animals  were  treated  with  TNF-α-ASON 
subconjunctival,  the  cytokine  expression  in  the  eyes  that  develop  acute  HSV-1 
retinitis  was  diminished  significantly.  As  no  such  effect  has  been  noted  with  the 
treatment of CON, this shows that this is a sequence specific ASON effect.
4.6 Design of the treatment protocol
We thought to block the TNF-α secretion in the contralateral eyes by the TNF-α-
ASON injections. The concentration used was adjusted to our previous studies, as 
discussed before. 
The amount of dye that was injected subconjunctivally was chosen: 1. as the volume 
could be easily injected into the subconjunctival  space without  significant  prompt 
leakage from the injection site, and 2. it did not induce a significant proptosis of the 
eye. The frequency of the subconjunctival injections was chosen: 1. as the previous 
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FITC-ASON in vitro and in vivo uptake studies suggested stable uptake into cultured 
cells  and  eye’s  structures,  e.g.  choroid  and retina,  was  achieved for  the  intervals 
applied, 2. no significant tissue damage of the eyes was noted in the cultured cells and 
eye tissues when these intervals were applied, 3. a significant reduction of the TNF-α 
secretion was achieved with this TNF-α-ASON amount.
The frequency of the intraocular injections was also chosen with consideration of 
these  aspects.  However,  several  major  disadvantages  occurred  with  the  repeated 
intraocular  injections.  1.  The  injections  induced  a  significant  damage  of  the 
intraocular tissues in the eyes. The pars plana area that was chosen for the injections is 
the preferred area  of  injecting  dye  into  the  vitreous  cavity,  as  the  lens  is  located 
anteriorly  and  the  retina  is  attached  more  posteriorly.  However,  no  needle  is 
commercial available for this procedure, so that glass capillaries were used. While 
these smallest diameter needles were still patent for the dye, damage to the lens or the 
retina were still seen in several of the mice, and the probability of the tissue damage 
increased with the number of the injections; 2. The puncture side did not completely 
heal until the subsequent repeated injections, which consequently led to leakage of the 
ASON dye; 3. The leakage of injected ASON solution into the subconjunctival space 
and  its  subsequent  drainage  via  the  lymphatic  system  resulted  in  the  untoward 
influence of immune system outside the eye, namely in the regional lymph nodes..
4.7  Influence  of  subconjunctival  TNF-α-ASON  treatment  on  the  course  of 
experimental HSV-1 retinitis
In our study, after three subconjunctival treatments with TNF-α-ASON, only 14.3% 
animals had developed retinitis by day 8. The incidence of retinitis in TNF-α-ASON 
treatment group was lower than in the control group. Additionally, the contralateral 
retinitis in treatment group was less severe than in control group by day 8. There was 
less inflammatory cell infiltration in the posterior segment.
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There are several possible mechanisms by which TNF-α-ASON treatment may have 
achieved improvement of the contralateral retinitis. Antigen activation was required 
for the up-regulation of p75 and to a lesser extent p55 TNF-R and the acquisition of 
TNF responsiveness by different T-cell subsets in vitro, but more importantly at sites 
of inflammation (Ware et al., 1991; Brennan et al., 1992; Cope et al., 1995). CD4+ T 
cell subsets contribute to the destruction of the retina, and may accelerate the cellular 
infiltration and inflammation-induced retinal destruction in von Szily model (Azumi 
et al., 1994). TNF-α-ASON can block the production of TNF-α that enhances T cell 
proliferation and differentiation.
Activated macrophages can express NOS2 and generate nitrite, peroxy-nitrites, and 
superoxides, which induce lipid peroxidation of cell membranes and cell death. TNF 
refers  to  stimulate  macrophage together  with  IFN-g.  In  previous  experiments,  the 
blockade of TNF-α activity resulted in a reduced NOS2 expression from lymph nodes 
and macrophages (Engwerda et al., 2002; Fonseca et al., 2003).
It is tempting to speculate that the reduction of TNF-α secretion may also be apparent 
in resident cells of the retina and choroid. Zheng reported that RPE cells and activated 
Müller  cells  expressed  TNF-α  in  von  Szily  model  (Zheng  et  al.,  2005).  As  a 
consequence, reduction of TNF-α expression in these cells may be in part responsible 
for the improvement of acute retinitis obtained by TNF-α-ASON treatment. Indeed, 
our studies with FITC-TNF-α-ASON indicated that Müller cells are able to take up 
ASON after subconjunctival injection
The  histological  results  in  our  experiments  showed  that  the  numbers  of  PMN, 
lymphocytes and monocytes were reduced in  the choroid and retina after  TNF-α-
ASON treatment.  The immunohistochemical studies disclosed that CD11b positive 
cells were decreased in the choroid and retina after TNF-α-ASON treatment. Together 
with the finding that there were fewer F4/80 positive cells in the TNF-α-ASON mice 
this is suggesting that PMN and macrophage numbers are reduced in the choroid and 
retina by the treatment. The IA/IE expression was slightly reduced in the choroid and 
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retina after TNF-α-ASON treatment. Also, the CD3 positive cells were also reduced 
in the choroid and retina of the TNF-α-ASON treated mice. 
Taken together, the TNF-α-ASON treatment influenced a broad array of inflammatory 
events in the choroid and retina. It is possible that TNF-α inhibition reduces the influx 
of inflammatory cells into the uvea and retina.  By TNF-α inhibition,  reduction of 
chemokines and adhesion molecules may be induced. It is also possible that TNF-α-
ASON  results  in  reduced  leukocyte  proliferation,  reduced  antigen  presentation, 
reduced apoptosis of APC and reduced matrix metalloproteinase (MMP) secretion.
In the later phase of retinal necrosis (day 10 PI), the animals that received TNF-α-
ASON treatment had increased incidence of retinitis and more severe retinitis. The 
histological studies showed that the number of inflammatory cells infiltrating in the 
posterior  segment  had  increased.  Our  further  immunohistochemical  investigation 
supported the notion that the total number of infiltrating cells increased between day 8 
and 10 PI. The inflammatory cells mainly belonged to PMN and T cells. Interestingly, 
the composition of the cells changed slightly after the subconjunctival TNF-α-ASON 
treatment as compared to the CON and PBS treated mice. After the TNF-α-ASON 
treatment, the number of CD-11b cells had decreased, while the percentage of CD3 T 
cells had increased. 
The increasing retinitis incidence and severity between the days 8 and 10 PI might 
also be related to the ASON-administration that was chosen. It has been described 
previously that  TNF-α mRNA and protein is  up-regulated during the evolution of 
experimental  retinal  necrosis  (from  day  6  to  14  PI)  in  the  contralateral  eyes  as 
compared with the levels in control subjects (Zheng et al., 2005). Our FITC-TNF-α-
ASON  experiments  revealed  a  veining  of  fluorescence  in  retina  at  3  days  after 
injection. However, in our experiments, the last administration of TNF-α-ASON was 
performed  on  day  4  PI.  in  order  to  achieve  profound  TNF-α  blockade  in  the 
development  phase  of  retinal  disease.  Due to  the increased sensitivity  of  mice  to 
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general  anesthesia  and  death  during  the  later  phase  of  the  von  Szily  model,  no 
additional injection was attempted. However, higher TNF-α-ASON concentration in 
the eye might have been achieved by additional subconjunctival injections at later 
time points.  Consequently,  application of TNF-α ASON at  later  time-points might 
have been superior in order to improve retinitis. 
Interestingly,  the virus titer  in the eyes of the TNF-α-ASON treatment  group was 
slightly higher than in the control group on day 10. It is well known that TNF-α plays 
an import role in antiviral during the virus infection. The role of TNF-α for the control 
of virus can be explained by several direct and indirect antiviral effects. It has been 
described  that  TNF-α induces  NO/ROS and phagocytosis  in  macrophages.  TNF-α 
induces  expression  of  adhesion  molecules  an  endothelial  cells.  TNF-α  enhances 
maturation of Th1 cells and activates NK cells and macrophages. TNF-α enhances 
migration of APC and macrophages to regional lymph nodes and their  maturation 
(Robertson et al., 2002; Cope et al., 1995).
TNF-α has synergy with IL-12 in enhancing NK cell IFNα production (Lucin et al., 
1994; Heise & Virgin, 1995). The antiviral function of TNF-α may be of particular 
importance in the von Szily model, as the damage of retina in retinal necrosis phase is 
connected to the viral replication.
In our experiments, the subconjunctival TNF-α-ASON injection at the contralateral 
eye affected the systemic immune response against HSV-1. TNF-α-ASON reduced 
HSV-1 specific T cell-proliferation in cells from contralateral regional lymph nodes. 
The CD4+ T cells are involved in virus clearance from contralateral eye (Azumi et al., 
1994). This is another explanation why the virus titer was higher in TNF-α-ASON 
treatment  group  than  in  the  control  group.  As  a  consequence,  subconjunctival 
treatment with TNF-α-ASON combined with systemic antiviral drug might be more 
effective  in  improving  the  course  of  contralateral  retinitis  than  the  use  of  TNF-α 
inhibitors alone. 
53
4.8  Influence  of  intraocular  TNF-α-ASON  treatment  on  the  course  of 
experimental HSV-1 retinitis
Our  observations  show  that  the  incidence  of  contralateral  retinitis  did  not  differ 
significantly  between PBS and TNF-α-ASON treatment  group (55% and 41.18%) 
when intraocular injections were performed on the days –1, +1, +4 PI. Several issues 
must be discussed to explain the obvious difference between the treatment results of 
the subconjunctival and intraocular injection mode. 
1.  The  intraocular  injection  induced  a  significant  tissue  damage  of  the  eyes  as 
compared to the subconjunctival mode of injections. 2. The leakage after i.o. injection 
resulted  to  a  drainage to  the  regional  lymph nodes,  while  the  intraocular  TNF-α-
ASON may by particularly drained to the spleen.
2.  The  leakage  from  the  subconjunctival  space  influenced  the  systemic  immune 
responses, as the HSV-1 specific T cell proliferative response in the regional lymph 
nodes was reduced with TNF-α-ASON as compared to the PBS treatment. In contrast, 
the HSV-1 specific proliferation of T cells harvested from the spleen did not differ 
between the TNF-α-ASON and PBS treated groups of mice.
3. In our experiments, FITC-TNF-α-ASON was detected in the retinal vessels and the 
retinal cells up to 3 days after intraocular injection. Previous experiments have shown 
that the mRNA level of TNF-α is elevated on day 6 PI., and subsequently decreased. 
The TNF-α expression in contralateral is significantly increased on the days 6, 9 and 
14 PI. (Zheng et al,. 2005). As a consequence of our experiments done so far, the 
intraocular  injection  should  only  be  performed  once  in  order  to  minimize  tissue 
damage of the eye and may be performed on day 7 PI. in order to achieve a maximum 
of TNF-α inhibition. 
4.  The  age  of  the mice that  were  used for  the  von Szily  experiments  may be  of 
particular importance for the course of HSV-1 encephalitis and retinitis. Due to the 
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maturation of the immune responses, older mice may be more resistant against HSV-1 
induced retinitis and encephalitis.  In one of our experiments,  the age of the mice 
varied between 6 and 12 weeks. The low incidence of contralateral disease noted in 
these experiments might be related to this notion. On the contrary, young mice are 
generally more susceptible to HSV-1 induced encephalitis and retinitis. Although the 
high retinitis  incidence is favorable for the experiments,  the high mortality of the 
young mice is a major disadvantage. Therefore, the use of mice between the ages of 6 




Antisense-oligonucleotides  targeting  tumor  necrosis  factor-alpha  in  murine 
herpes simplex virus type 1 retinitis. 
Purpose: To  investigated  whether  topical  tumor  necrosis  factor-alpha  (TNF-α)-
antisense-oligonucleotides (ASON) treatment might affect the course of contralateral 
HSV-retinitis.
Methods: In  vivo  uptake  was  determined  after  subconjunctival  (s.c.)  injection  of 
FITC-labeled TNF-α-ASON. BALB/c mice were injected in the AC of the right eyes 
with  HSV-1  (KOS);  the  left  eyes  were  injected  s.c.  3  times  with  TNF-α-ASON; 
sequence-unspecific control (C) ON or buffer. The clinical course of HSV-R, ocular 
inflammatory  cell-infiltration,  uptake  of  [3H]thymidine  from  rLN  cells  and  viral 
replication in the eyes were analyzed. 
Results: In vivo, FITC-TNF-α-ASON was found in the choroid and retina up to 7 
days  after  s.c.  injection,  but  also  in  the  rLN.  After  s.c.  TNF-α-ASON  injection, 
expression  of  TNF-α was  reduced in  the  ipsilateral  eyes  and  rNL.  TNF-α-ASON 
injection  reduced  the  incidence  and  severity  of  early  chorioretinitis  and  of  the 
inflammatory cell infiltration and CD-11b cells in the choroid and retina of the treated 
eye.  On day 10 PI,  the virus titers,  inflammatory cell  infiltration and HSV-R had 
increased in the TNF-α-ASON treated eyes, while the HSV-1 specific [3H]thymidine 
uptake from rLN cells was decreased and DTH response did not differ between the 
PBS, CON and TNF-α-ASON groups.
Conclusions: Topical TNF-α-ASON-injection reduced early ocular inflammatory cell 
infiltration, but delayed the virus clearance and increased the severity of HSV-retinitis 
in the treated eyes. The antisense technique is a useful experimental approach for the 
topical application of TNF-α in experimental HSV-1 retinitis. 
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Fig  1  Distribution  of  HSV-1  antigen  in  the  eyes,  the  optic  nerve  and  autonomic 
structures at different time-points after infection. Infected areas are stippled. Numbers 
in  parentheses  indicate  mean  delay  to  detection  of  viral  antigens  (days  PI). 
Abbreviations:  AH,  anterior  hypothalamic  nucleus;  CB,  ciliary  body;  CG,  ciliary 
ganglion;  EW,  Edinger-Westphal  nucleus;  LGN,  lateral  geniculate  nucleus;  MPA, 
medial pretectal area; OC, optic chiasm; OM, nucleus of the oculomotor nerve; ON, 
optic  nerve;  PH,  paraventricular  hypothalamic  nucleus;  SCN,  suprachiasmatic 
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nucleus; Ⅲ, oculomotor nerve. (Fig. 13 in Vann et al., 1991).
Figure 2
Fig 2  Comparison of different antisense strategies. While most of the conventional 
72
drugs  bind  to  proteins,  antisense  molecules  pair  with  their  complementary  target 
RNA.  Antisence-oligonucleotides  block  translation  of  the  mRNA  or  induce  its 
degradation  by  RNase  H,  while  ribozymes  and  DNA enzymes  possess  catalytic 
activity  and cleave their  target  RNA. RNA interference approaches are performed 
with siRNA molecules that are bound by the RISC and induce degradation of the 
target mRNA. (Fig. 1 in Kurreck et al., 2003).
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Figure 3
Fig 3  Mechanisms of antisense activity. (A) RNase H cleavage induced by ASON. 




Fig  4   Fluorescence  staining  of  cells  derived  from  regional  lymph  nodes.  After 
cultured  with  FITC-labeled  ASON  for  12  hours,  the  cells  were  examined  by 
fluorescence- and light microscopy. (A) Fluorescence was observed in the cells of 




Fig 5  Flow cytometric analysis of cells derived from regional lymph nodes.  Left 
trace: the negative control without FITC; broken trace: events after incubation solely 
with FITC (0.45% positive);  thick trace: event with FITC-labeled oligonucleotide 
(67.17%  positive).  Incubation  time,  15  minutes;  concentration,  2μM.  (Fig  1  in 






Fig 6  Fluorescence staining of different tissues 1 day after injection of FITC-ASON. 
After subconjunctival injection of 50μl FITC-TNF-α-ASON, the eyes and regional 
lymph  nodes  were  harvested  and  imbedded  in  paraffin,  and  5µm  sections  were 
prepared. (A) Subconjunctiva, iris and ciliary body were strongly fluorescent positive. 
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(B) No fluorescence was found in anterior segment of negative controls. (C) Sclera, 
choroid,  retinal  vessels  and  few cells  within  the  retina  were  strongly  fluorescent 
positive. (D) No fluorescent was found in the posterior segment of negative controls. 
(E) A few cells in regional lymph node were fluorescent positive. (F) No fluorescence 
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**
Fig 7 TNF-α content by ELISA assay in the different treatment groups on day 8. Mice 
were infected with 2×104 PFU of HSV into right eyes on day 0. After subconjunctival 
injection with TNF-α-ASON, CON or PBS, the content of TNF-α in left eye was 
examined on day 8. The TNF-α-content was significantly reduced after TNF-α-ASON 
treatment compared with PBS and CON treatment group. ** P<0.01 compared with 























HSV+PBS HSV+CON HSV+TNF- α - ASON
*
Fig 8 Clinical incidence of retinitis on day 8 after subconjunctival treatment. Mice 
were infected with 2×104 PFU of HSV into right eyes on day 0. After subconjunctival 
injection with TNF-α-ASON, CON or PBS, the left eyes were examined on day 8. 
Mice treated with TNF-α-ASON had reduced incidence of retinitis as compared to the 





Fig 9  Histological findings in BALB/c mice on day 8 after HSV-1 infection. Mice 
were infected with 2×104 PFU of HSV into right eyes on day 0. After subconjunctival 
injection with TNF-α-ASON, CON and PBS, the left eyes were obtained by day 8, 
were sectioned and stained with hematoxylin and eosin (HE). (A) Mice treated with 
PBS had severe inflammatory cells infiltration and loss of retinal  architecture (B) 
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Treatment with CON (C) Mice treated with TNF-α-ASON had reduced inflammatory 

















Fig 10 Degree of retinitis on day 8 after infection in the different treatment groups. 
Mice  were  infected  with  2×104 PFU  of  HSV  into  right  eyes  on  day  0.  After 
subconjunctival  injection  with  TNF-α-ASON,  CON  and  PBS,  the  left  eyes  were 
harvested by day 8,  sectioned and stained with hematoxylin  and eosin (HE).  The 
retina was graded from 0 to 2+, depending on the retinitis and necrosis extension. 
Animals  treated  with  TNF-α-ASON  had  less  severe  retinitis  than  PBS  treatment 
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Fig 11 Number of inflammatory cells in ciliary body and choroid on day 8 in the 
different treatment groups. Mice were infected with 2×104 PFU of HSV into right 
eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and PBS, the 
left eyes were cut into sections and stained with hematoxylin and eosin (HE). The 
number  of  inflammatory  cells  was  counted  in  a  high-power  field.  (magnification, 
×400). Compared with the control groups, the mice with TNF-α-ASON treatment had 
less the inflammatory cells in ciliary body and choroid.  Data are the mean ± SD. * 





Fig  12   Immunohistochemical  findings  in  BALB/c  mice  on  day  8  after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV into right eyes on day 0. After 
subconjunctival injection with TNF-α-ASON, CON and PBS the left eyes were cut 
into sections and stained by immunohistochemistry (CD11b). (A) Retina of the left 
eye, treatment with PBS: heavy CD11b positive cell infiltration and loss of normal 
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retinal architecture. (B) Left eye of mouse with  CON treatment had severe CD11b 
positive cells infiltration and loss of normal retinal architecture. (C) Left  retina of 
mouse after treatment with TNF-α-ASON had fewer CD11b positive cells and only a 
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Fig 13 Number of CD11b positive cells in ciliary body, retina and choroid on day 8 
with different treatment protocols. Mice were infected with 2×104 PFU of HSV into 
right eyes on day 0. After subconjunctival injection of TNF-α-ASON, CON and PBS, 
the left eyes were sectioned and processed by immunohistochemistry. The number of 
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CD11b  positive  cells  was  counted  in  a  high-power  field  (magnification,  ×400). 
Animals treated with TNF-α-ASON had significantly fewer CD11b positive cells than 




Fig  14    Immunohistochemical  findings  in  BALB/c  mice  on  day  8  after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV into right eyes on day 0. After 
subconjunctival injection of TNF-α-ASON, CON and PBS, the left eyes were cut, and 
sections were stained with mAb directed against CD3. (A) PBS group: severe CD3 
cell infiltration in choroid and loss of normal retinal architecture. (B) CON group: 
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severe CD3 cells infiltration in choroid and loss of normal retinal architecture. (C) 
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*
Fig 15 Number of CD3 positive cells in ciliary body, retina and choroid on day 8 in 
the different treatment groups. Mice were infected with 2×104 PFU of HSV into right 
eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and PBS, the 
left  eyes  were  harvested,  sectioned  and  stained  by  immunohistochemistry.  The 
number  of  CD3 positive  cells  was  counted in  a  high-power field.  (magnification, 
×400). Animals treated with TNF-α-ASON had significantly fewer CD3 positive cells 






Fig  16  Immunohistochemical  findings  in  BALB/c  mice  on  day  8  after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV into right eyes on day 0. After 
subconjunctival  injection  of  PBS,  CON  and  TNF-α-ASON,  the  left  eyes  were 
obtained,  sectioned  and  stained  by  immunohistochemistry  (F4/80).  (A)  Treatment 
with  PBS:  few  F4/80  positive  cells  and  loss  of  normal  retinal  architecture.  (B) 
93
Treatment with CON: few F4/80 positive cells and loss of normal retinal architecture. 
(C) Treatment with TNF-α-ASON: few F4/80 positive cells and the nearly normal 
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Fig 17 Number of F4/80 positive cells in ciliary body, retina and choroid on day 8 in 
the different treatment groups. Mice were infected with 2×104 PFU of HSV into right 
eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and PBS, the 
left  eyes  were  harvested,  sectioned  and  processed  by  immunohistochemistry.  The 
number of F4/80 positive cells was counted in a high-power field. (magnification, 
×400). Animals treated with TNF-α-ASON and CON had significantly fewer F4/80 






Fig  18    Immunohistochemical  findings  in  BALB/c  mice  on  day  8  after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV into right eyes on day 0. After 
subconjunctival  injection  with  TNF-α-ASON,  CON  and  PBS,  the  left  eyes  were 
harvested and cut into sections and stained by immunohistochemistry (IA/IE). (A) 
Mice treated with PBS had severe IA/IE positive cell infiltration in choroid and loss 
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normal retinal architecture. (B) Mice treated with PBS had severe IA/IE positive cell 
infiltration in choroid and loss of normal retinal architecture. (C) Mice treated with 
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Fig 19 Number of IA/IE positive cells in ciliary body, retina and choroid on day 8 in 
the different treatment groups. Mice were infected with 2×104 PFU of HSV in the 
right eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and 
PBS, the left eyes were obtained, sectioned and assayed with immunohistochemistry. 
The number of IA/IE positive cells was counted in a high-power field. (magnification, 
×400). Animals treated with TNF-α-ASON and CON had significantly fewer IA/IE 
positive  cells  than  PBS  treatment  group  in  ciliary  body.  Mean  ± SD.  *  P<0.05 
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Fig 20 Clinical incidence of retinitis on day 10 after subconjunctival treatment. Mice 
were infected with 2×104 PFU of HSV into right eyes on day 0. After subconjunctival 
injection with TNF-α-ASON, CON or PBS, the left eyes were examined on day 10. 




   
Fig 21   Histological findings in BALB/c mice on day 10 after HSV-1 infection. Mice 
were infected with 2×104 PFU of HSV in the right eyes on day 0. After 
subconjunctival injection with TNF-α-ASON and PBS, the left eyes were harvested, 
sectioned and stained with hematoxylin and eosin (HE). (A) Treatment with PBS: 
severe inflammatory cell infiltration and loss normal retinal architecture. (B) CON 
102
treatment: severe inflammatory cell infiltration and loss of normal retinal architecture 
(C) Treatment with TNF-α-ASON: severe inflammatory cell infiltration and loss of 




Fig  22  Immunohistochemical  findings  in  BALB/c  mice  on  day  10  after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV into right eyes on day 0. After 
subconjunctival  injection  with  TNF-α-ASON,  CON  and  PBS,  the  left  eyes  were 
harvested, cut into sections and stained with mAb directed against CD11b. (A) Mice 
reated with PBS had severe CD11b positive cell infiltration and loss of normal retinal 
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architecture. (B) Mice treated with CON had severe CD11b positive cell infiltration 
and loss of normal retinal architecture. (C) Mice treated with TNF-α-ASON had mild 
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Fig 23 Number of CD11b positive cells in ciliary body, retina and choroid on day 10 
in the different treatment groups. Mice were infected with 2×104 PFU of HSV in right 
eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and PBS, the 
left  eyes  were  obtained,  sectioned  and  processed  by  immunohistochemistry.  The 
number of CD11b positive cells was counted in a high-power field. (magnification, 
×400). Animals treated with TNF-α-ASON had significantly fewer CD11b positive 
cells than PBS treatment group in retina and choroid. Mean ± SD. * P<0.05 compared 





Fig 24   Immunohistochemical  findings in  BALB/c mice on day 10 after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV in the right eyes on day 0. 
After subconjunctival injection with TNF-α-ASON, CON and PBS, the left eyes were 
harvested,  sectioned  and  stained  with  mAb directed  against  CD3.  (A)  Mice  after 
treatment with PBS had severe CD3 positive cell infiltration. (B) Mice after treatment 
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with  CON  had  severe  CD3  positive  cell  infiltration  in  choroid.  (C)  Mice  after 
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Fig 25 Number of CD3 positive cells in ciliary body, retina and choroid on day 10 in 
the different treatment groups. Mice were infected with 2×104 PFU of HSV in the 
right eyes on day 0. After subconjunctival injection with TNF-α-ASON, CON and 
PBS, the left eyes were obtained, sectioned and stained with mAb directed against 
CD11b.  The  number  of  CD11b positive  cells  was  counted in  a  high-power  field. 
(magnification, ×400). Animals treated with TNF-α-ASON had significantly reduced 
number of CD3 positive cells in the retina than PBS treatment group. Mean ± SD. * 






Fig 26 Immunohistochemical findings in BALB/c mice on day 10 after HSV-1 
infection. Mice were infected with 2×104 PFU of HSV in the right eyes on day 0. 
After subconjunctival injection with TNF-α-ASON, CON and PBS. mAb against 
F4/80. (A) After treatment with PBS: severe F4/80 positive cell infiltration. (B) After 
treatment with CON: mild F4/80 positive cell infiltration. (C) After treatment with 
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Fig 27 Number of F4/80 positive cells in ciliary body, retina and choroid on day 10 in 
the different treatment groups. Mice were infected with 2×104 PFU of HSV in the 
right eyes on day 0. Subconjunctival injection with TNF-α-ASON, CON and PBS; 
day 10. High-power field. (magnification, ×400). Animals treated with TNF-α-ASON 
had significantly fewer F4/80 positive cells than PBS treatment group in retina and 




Fig 28   Immunohistochemical  findings in  BALB/c mice on day 10 after  HSV-1 
infection. (A) Treatment with PBS: heavy IA/IE positive cell infiltration in choroid. 
(B)  Treatment  with  PBS:  severe  IA/IE  positive  cell  infiltration  in  choroid.  (C) 





























HSV+PBS HSV+CON HSV+TNF-α -ASON
Fig 29   Number of IA/IE positive cells in ciliary body, retina and choroid on day 10 
in  the  different  treatment  groups.  (magnification,  ×400).  No significant  difference 
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Fig 30 DTH assay in BALB/c mice on day 10 after  HSV-1 infection.  Mice were 
infected with 2×104 PFU of HSV in the right eyes on day 0. After subconjunctival 
injection with TNF-α-ASON, CON or PBS, HSV-1-specific DTH was calculated on 
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Fig 31 T cell proliferation in BALB/c mice on day 10 after HSV-1 infection. Mice 
were  infected  with  2×104 PFU  of  HSV  in  the  right  eyes  on  day  0.  After 
subconjunctival injection with TNF-α-ASON, CON or PBS,  the left regional lymph 
nodes were examined on day 10. Stimulation with UV-inactivated HSV-1, counts per 
minute  measured  as  uptake  of  [3H]thymidine.  Sc  TNF-α-ASON injection  reduced 


















Fig 32 Plaque Forming Unit assay in BALB/c mice on day 10 after HSV-1 infection. 
Mice were infected with 2×104 PFU of HSV in the right eyes on day 0. After 
subconjunctival injection with TNF-α-ASON, CON or PBS, the PFU in left eye were 
calculated on day 10. The virus titers were increased in the TNF-α-ASON treatment 





Fig 33 Fluorescence staining of eyes 1 day after intraocular FITC-ASON injection. 
After 2μl FITC-TNF-α-ASON was injected into the vitreous, the eyes were collected, 
imbedded  in  paraffin  and  5µm  sections  were  prepared.  (A)  The  endothelium  of 
cornea, iris and ciliary body were strongly fluorescent positive. (B) No fluorescent 
was found in anterior segment of the negative control.  (C) Ganglionic cells of the 
retina and retinal vessels were strongly fluorescent positive. (D) No fluorescent was 
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Fig 34 TNF-α content in the eyes by ELISA assay in the different treatment groups on 
day 8. Mice were infected with 2×104 PFU of HSV in the right eyes on day 0. After 
intraocular injection with TNF-α-ASON, CON or PBS three times,  the content  of 
TNF-α in  left  eye  was examined on day 8.  The  TNF-α content  was  significantly 
reduced after TNF-α-ASON treatment as compared to the PBS and CON treatment 
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Fig 35 Incidence of retinitis on day 8 after intraocular treatment. Mice were infected 
with 2×104 PFU of HSV into right eyes on day 0. After 3x intraocular injection of 
TNF-α-ASON, CON or PBS, the left eyes were examined on day 8. There was no 




Fig 36 Histological findings in BALB/c mice on day 8 after HSV-1 infection. 3x 
intraocular injection with TNF-α-ASON, CON and PBS the left eyes. (A) PBS: had 
severe inflammatory cell infiltration and loss of normal retinal architecture. (B) CON: 
severe inflammatory cell infiltration and loss of normal retinal architecture. (C) TNF-


















Fig 37 Degree of  retinitis  on day 8 in  the different  treatment  groups.  Mice were 
infected with 2×104 PFU of HSV into right eyes on day 0. 3x intraocular injection 
with TNF-α-ASON, CON and PBS. Hematoxylin and eosin (HE).  The retina was 
graded from 0 to 2+, depending on the retinitis and necrosis extension. There was no 
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Fig 38 Number of inflammatory cells in ciliary body and choroid on day 8 in the 
different treatment groups. Mice were infected with 2×104 PFU of HSV in the right 
eyes on day 0.  After  3x intraocular  injection with TNF-α-ASON, PBS and CON. 
Hematoxylin and eosin (HE). The number of inflammatory cells was counted in a 
high-power field. (magnification, ×400). The number of inflammatory cells in ciliary 
body and choroid were not significantly different in the treatment groups. Data are the 
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Fig 39 Incidence  of  retinitis  on day 10 after  3x intraocular  treatment.  Mice  were 
infected with 2×104 PFU of HSV in the right eyes on day 0. After 3x intraocular 
injection with TNF-α-ASON, CON or PBS, the left eyes were examined on day 10. 
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*
Fig 40 DTH assay in BALB/c mice on day 10 after  HSV-1 infection.  Mice were 
infected  with  2×104 PFU of  HSV into  right  eyes  on  day  0.  After  3x  intraocular 
injection with TNF-α-ASON, CON or PBS, the HSV-1-specific DTH was determined 
on day 10. The mice in TNF-α-ASON group had significantly reduced DTH reaction 





















HSV+PBS HSV+CON HSV+TNF- α - ASON
** **
Fig 41 HSV-1 T cell  proliferation assay in BALB/c mice on day 10 after  HSV-1 
infection. Mice were infected with 2×104 PFU of HSV in the right eyes on day 0. 
After  3x intraocular  injection  with  TNF-α-ASON, CON or  PBS,  the left  regional 
lymph nodes  were  examined on  day  10.  Stimulation  with  UV-inactivated  HSV-1, 
counts  per  minute  measured  as  uptake  of  [3H]thymidine.  TNF-α-ASON  injection 





ACAID anterior chamber-associated immune deviation
AH anterior hypothalamic nucleus
ARN acute retinal necrosis
APC antigen presenting cell
APES 3-aminopropyltriethoxysilane
ASON antisense oligonucleotides




CNS central nervous system
CON control oligonucleotides 
DNA deoxyribonucleic acid
DTH delayed type hypersensitivity
EAU experimental autoimmune uveoretinitis
EW Edinger-Westphal nucleus
FCS fetal calf serum
FITC fluorescein isothiocyanate 
GCL ganglion cell layer
HRP horseradish peroxidase
HSK herpetic stromal keratitis 
HSV herpes simplex virus
IFN interferon
LGN lateral geniculate nucleus
IL interleukin
LN lymph node
MIP macrophage inflammatory protein
MMP matrix metalloproteinase
MPA medial pretectal area
NK nature kill cells
NO nitric oxide
NOS2 nitric oxide synthase
OC optic chiasm
OM nucleus of the oculomotor nerve
ON optic nerve
PBS phosphate buffered saline
PFU plaque forming units





ROS reactive oxygen species




siRNA short interfering RNA 
TNF-α tumor necrosis factor alpha
UV ultraviolet
VZV varicella zoster virus
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